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Introduction: Non-alcoholic fatty liver disease (NAFLD) is a heterogeneous condition and 
at least two different forms exist. ‘Obese/Metabolic NAFLD’ characterizes subjects with 
metabolic syndrome and insulin resistance, whereas NAFLD associated with the common 
PNPLA3 I148M variant (‘PNPLA3 NAFLD’) is not accompanied by insulin resistance. The 
aims of the present studies were to determine 1) whether genetic variation in APOC3 
contributes to liver fat content and plasma triglyceride and apoC3 concentrations, 2) the 
prevalence of non-alcoholic steatohepatitis in Finnish subjects, and 3) how the PNPLA3 gene 
variant influences the serum lipidome. 
Subjects and methods: The study groups consisted of 417 (I) and 372 (III) subjects, as well 
as 296 bariatric surgery patients from Finland and 2849 subjects from a population-based 
D2D-sample (II). In Study II, 380 non-bariatric surgery patients who had undergone a liver 
biopsy for suspected NAFLD from Italy were used as an external validation cohort. In Study 
I liver fat content was measured by proton magnetic resonance spectroscopy (1H-MRS), in 
Study II by either biopsy or 1H-MRS, and in Study III in 75% by 1H-MRS and in 25% by 
biopsy.  Clinical characteristics (I, II, III), plasma apoC3 concentrations (I), and serum 
cytokeratin 18 fragments (II) were determined. In Study III, lipidomic analyses were 
performed using ultra-performance liquid chromatography coupled to time-of-flight mass 
spectrometry (UPLC-MS). Individuals were genotyped for rs2854116 and rs2854117 in 
APOC3 (I) and the known rs738409 in PNPLA3 (I, II, III). In Study II, we developed and 
validated a ‘NASH score’ in the Finnish and Italian biopsy cohorts, which was then used to 
predict NASH prevalence in the population-based D2D study. In Study III, the subjects were 
divided into groups based on PNPLA3 genotype or obesity, and the absolute and relative 
triacylglyceride concentrations were compared between the subgroups. 
Results: No difference existed between the APOC3 variant allele (T-455C or C-482T or 
both) carriers and non-carriers in liver fat or apoC3 concentrations, whereas those with the 
PNPLA3 GG genotype at rs738409 had a 2.7-fold higher liver fat content than those with the 
CC genotype (I). The ‘NASH score’ included PNPLA3 genotype, aspartate aminotransferase 
(AST), and fasting insulin. The area under the ROC for this score was 0.774 (95% CI 0.709-
0.839) in Finns and 0.759 (95% CI 0.711-0.807) in Italians (NS) (II). The prevalence of 
NASH based on this score in the D2D study was 6.0% (95% CI 5.0-6.9%) (II). Sensitivity 
analysis was performed by a Bayesian model, which gave a NASH population prevalence of 
3.6% (95% CI 0.2-7.7%) using the ‘NASH Score’ (II).  Absolute and relative deficiency of 
distinct circulating TAGs was observed in the PNPLA3148MM/148MI as compared with the 
PNPLA3148II group (III). Genotypes in the obese and ‘non-obese’ groups were similar but the 
obese subjects were insulin-resistant (III).  Liver fat was increased in both obese and 
PNPLA3148MM/148MI groups (III). Multiple changes in the relative TAG concentrations were 
observed between obese and ‘non-obese’ groups (III). These closely resembled those 
between obese subjects with ‘obese NAFLD’ versus the ‘PNPLA3 NAFLD’ (III). 
Conclusions: Variation in liver fat cannot be explained by genetic variants in APOC3 (I). 
The population-based prevalence of NASH in Finnish subjects is ~5% (II). The circulating 
TAG profile depends on the aetiology of NAFLD (III). In ‘PNPLA3 NAFLD’ a relative 
deficiency of TAGs is observed, supporting the idea that the I148M variant prevents lipolysis 
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INTRODUCTION 
 
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver 
disease in the Western world. NAFLD covers a spectrum of liver disease from simple 
steatosis to fatty infiltration with inflammation to hepatocellular ballooning degeneration 
(non-alcoholic steatohepatitis, NASH). The latter may progress to fibrosis and/or cirrhosis, in 
the absence of excess alcohol consumption (1).  
The increase in NAFLD prevalence parallels that of obesity. Insulin resistance and 
metabolic syndrome develop especially in those obese subjects with fatty liver, termed 
‘Obese/Metabolic NAFLD’ in the ensuing discussion (2). In this type of NAFLD, caloric 
excess and physical inactivity increase hepatic free fatty acid (FFA) influx and hepatic de 
novo lipogenesis (DNL), resulting in excess liver fat (3). This in turn leads to 
hypertriglyceridemia, hyperglycemia and hyperinsulinemia (3). 
A common I148M gene variant in PNPLA3 has been extensively studied and its 
robust association with accumulation of liver fat has been independently confirmed in 
numerous studies (4-9). NAFLD associated with PNPLA3 rs738409 (‘PNPLA3 NAFLD’) is 
not per se accompanied by insulin resistance or other metabolic abnormalities, such as 
hyperinsulinemia and hypertriglyceridemia, as seen in ‘Obese NAFLD’ (3).  Other genetic 
causes for NAFLD, such as variants in APOCIII (alleles T-455C and C-482T) have been 
suggested to exist (10) but have not been confirmed. ‘Obese/Metabolic NAFLD’ and 
‘PNPLA3 NAFLD’ may coexist (11). Changes in the distribution of circulating 
triacylglycerols (TAGs) in the two different types of NAFLD have not been investigated in 
humans. 
The pooled global prevalence of NAFLD is estimated to be around 25% (12). Fatty 
liver can be diagnosed reliably using imaging techniques, but diagnosis of NASH requires 
biopsy. Various clinical and biochemical markers have been combined to form diagnostic 
scores to predict NASH, but they lack diagnostic accuracy. Current biopsy-based prevalence 
estimates of NASH are from highly selected groups of patients, and no population-based 
estimates have been published. 
 
  
REVIEW OF THE LITERATURE 
 
1. Lipid metabolism under physiological conditions 
 
1.1. Overview 
Lipids can be divided into various groups based on their chemical structure. In terms of 
abundance the most prevalent are the triacylglycerides (TAGs) (13) . Another important 
group of lipids that are found in cell membranes and lipoproteins are phospholipids (PLs), 
which in addition act as precursors for signalling molecules such as diacylglyceride (DAG), 
phosphatidic acid, eicosanoids, and lyso-phospholipids (14).  Fatty acids (FAs) are the 
elementary units of fats and can be further divided into saturated- (SAFA), mono-
unsaturated- (MUFA), and polyunsaturated fatty acids (PUFA). FAs found in the diet contain 
mostly 16 or 18 carbons. Linolenic acid (LA, 18:2, n-6) and α-linolenic acid (ALA, 18:3, n-
3), and long-chain polyunsaturated fatty acids (PUFAs) produced from them, such as  
eicosapentaenoic acid acid (EPA, 20:5), docosapentaenoic acid (DPA, 22:5), and 
docosahexaenoic acid (DHA 22:6) from ALA, and γ-linolenic acid (GLA, 18:3), dihomo-γ-
linolenic acid (DGLA, 20:3), and arachidonic acid (AA, 20:4) from LA, cannot be 
synthesized by the body and are called essential fatty acids (15, 16). 
 
The transport of TAGs and FAs in the circulation differ due to a difference in their 
hydrophilic nature (17). FAs are transported in the plasma bound to albumin in a free, non-
esterified form (free fatty acid, FFA), whereas water-insoluble TAGs are transported in 
plasma by lipoproteins (14, 18, 19). Lipoprotein lipase (LPL, in muscle and adipose tissue) 
and the structurally related hepatic lipase (HL, in liver) release FAs from TAGs on the 
endothelial wall of capillaries (17), after which the FFAs cross the endothelial cell lining 
down a concentration gradient and/ or via FA transport proteins (FATPs) (20-22). 
 
Fat storage  
TAG droplets are concentrated energy stores and are mainly formed by either uptake of FAs 
from plasma TAGs (in lipoproteins) or by de novo lipogenesis (DNL, see below) (23). In a 
diet rich in dietary fats (e.g. Western diet), the more important route by far is uptake of 
plasma TAGs (24). The most important tissue for storage of fat is the adipose tissue. In the 
fed, high-insulin state, the adipose tissue LPL activity is enhanced and the freed FAs are 
taken up by adipocytes via passive diffusion and FAT/CD36 carriers (21, 22). After entering 




Fat mobilization from adipose tissue, on the other hand, is intensified by lowering of insulin 
concentration. Low insulin levels in the fasting state downregulate the adipocyte LPL 
resulting in lower FA influx (26), whereas increased intracellular hydrolysis leads to 
increased FA efflux (27). The hydrolysis of TAGs is carried out by the enzymes adipose 
triglyceride lipase (ATGL, removal of the first FA) and hormone-sensitive lipase (HSL, 
removal of the second FA) (28), which act on the surface of the TAG droplet. Removal of the 
third and last FA is carried out by monoacylglycerol lipase (14). The process results in one 
glycerol and three FA molecules, which mostly leave the cell and enter the circulatory FFA 
pool. Like LPL, HSL is regulated by insulin and remains active in the fasting state when 
insulin concentrations are low, and is on the contrary postprandially inactivated by high 
insulin levels (29).  
 
1.2. Liver lipids 
Lipid metabolism in liver includes both oxidation and synthesis of FAs. The main sources of 
liver FAs include FFAs liberated from adipose tissue, chylomicron remnants, or from the 
intestine via portal vein and from DNL (24) .  Upon hepatic uptake, the FAs can be directed 
to oxidation, ketone body formation, TAG droplets or phospholipid (PL) synthesis, or 
incorporated into VLDL. 
 
The synthesis of FAs from excess carbohydrates is called de novo lipogenesis (23), and 
although it is relatively small (less than 5% in fasting state) compared with dietary FA intake 
(18) it plays a key role in coordinating glucose and fat metabolism (30). De novo lipogenesis 
produces exclusively SAFAs such as 16:0 and 18:0. These can then be converted to 16:1 and 
18:1 FAs via the action of hepatic stearoyl CoA desaturase 1 (SCD-1)  (31). 
 
FAs enter the liver from the circulation as FFAs or from lipoproteins (see below) via 
lipolysis. When the insulin concentration is low (i.e. in the fasting state), most of the 
circulating FFAs originate from adipocyte TAG stores via lipolysis. These FFAs released 
from the adipose tissue account for 80% of the FAs incorporated into VLDL in the liver (18). 
 
Fatty acid oxidation and storage 
In the fasting state, when insulin concentrations are low and those of glucagon high, FAs are 
directed mainly into mitochondrial beta-oxidation to produce energy (32) as well as into 
VLDL synthesis, instead of storage (18). During the oxidation ketone bodies are produced 
and released into the circulation.  
 
When insulin concentrations increase in the fed state the FAs are directed into the liver TAG 
droplets for storage (25), and not into VLDL synthesis (18). This results from the suppression 
of VLDL assembly, as well as lowering of hepatic FFA uptake by insulin (26). 
 
De novo lipogenesis (DNL) 
Another pathway stimulated by insulin and primarily active in the liver is DNL. In this 
pathway, glucose or other simple sugars or amino acids are taken up by the hepatocyte, and 
after passing through the glycolytic and tricarboxylic pathway exit the mitochondrion as 
citrate. Cytoplasmic enzymes catalyse the conversion of citrate into malonyl-CoA (23), 
which is a key regulator between carbohydrate and fat metabolism (33). The main product of 
DNL is palmitate, but also stearate and shorter SAFAs are produced. 
 
Under normal conditions, DNL is believed to be a minor contributor to serum TAGs (24). 
Nevertheless, it has been shown that a diet rich in carbohydrates (especially fructose) 
increases hepatic DNL contributing to hypertriglyceridemia (34). High carbohydrate intake 
activates DNL in the liver and increases synthesis of VLDL (35). 
 
1.3. Circulating lipids 
Lipids such as FFAs and TAGs are hydrophobic and therefore need carriers for transport in 
the circulation. FFAs are bound to albumin, whereas TAGs and cholesterol are carried in 
lipoproteins, which are lipid droplets surrounded by a layer of  membrane phospholipids.  
Lipoproteins and apolipoproteins 
Lipoproteins exist with different lipid and protein compositions, which affect their size. The 
chylomicrons (CMs) and VLDL are rich in TAGs and larger than LDL and HDL, which are 
enriched in cholesterol and involved in cholesterol transport to and from cells (36). 
Apolipoproteins are specific, lipoprotein-associated proteins that control cellular uptake of 
lipoproteins by binding to membrane lipoprotein receptors (37). Lipoprotein metabolism 
includes the exogenous and endogenous pathways as well as the reverse cholesterol transport. 
The exogenous lipoprotein metabolism pathway 
In the enterocytes absorbed dietary TAGs are incorporated into CMs with apolipoprotein B48 
(apoB48) (37), apoAIV and apoAV. They later acquire additionally apoAI, apoAII, and apoC 
(apoCI, apoCII and apoCIII), and finally, apoE. Functions of apolipoproteins are class- and 
isoform-specific. ApoB84, apoB100 and apoE function as receptor ligands (36), whereas 
apolipoprotein AI, the best characterized of its class, is an activator of the enzyme lecithin-
cholesterol acyl transferase (LCAT). ApoCII is an essential activator (36) and apoCIII an 
inhibitor of LPL (37). 
CM-TAGs undergo intravascular hydrolysis by the insulin-activated LPL (38), resulting in 
FFA delivery to  cells. Various apolipoproteins are returned to HDL, and, as a result, the size 
of CMs decrease and they become CM remnants. These are subsequently taken up by the 
liver after apoE binds to the lipoprotein receptor-related protein (LRP) or the LDL receptor 
(39). 
The endogenous lipoprotein metabolism pathway  
In the endogenous pathway, TAGs are secreted from the liver in VLDL particles, which 
contain apoB100 and subsequently acquire apoA, apoC, and apoE (37) mostly from HDL. In 
the periphery VLDL-TAG is hydrolysed by LPL transforming the VLDL into remnants (40), 
which in turn bind the hepatic LDL receptor. The apolipoproteins lost in the process are 
transferred to HDL. Binding of the VLDL particles is accompanied by further hydrolysis by 
HL, after which the depleted particle may be removed by receptors or converted into LDL 
(41), which remains in the circulation. In the blood, both VLDL and LDL lose some of their 
TAGs to HDL in exchange for cholesteryl esters (42), mediated by cholesteryl ester transfer 
protein (CETP) (43). HDL is the smallest of the lipoproteins and is responsible for the 
removal of cholesterol from the peripheral tissues and its transport to the liver for excretion 
(44, 45), which is sometimes called the reverse cholesterol transport (RCT). 
 
Molecular lipids 
In addition to the above-mentioned major lipid species, various smaller groups of lipids, 
including sphingomyelins, ether-linked lipids, lysophosphatidylcholines, ceramides, 
eicosanoids, and lyso-phospholipids, etc., exist in the body and can be identified and 
quantified by ultra-performance liquid chromatography coupled to time-of-flight mass 
spectrometry (UPLC-MS) (46). Identification of these lipids is currently a hot topic in lipid 
and NAFLD research in order to better understand their contribution in health and disease. 
  
2. Non-alcoholic fatty liver disease (NAFLD) 
 
2.1 Definition and disease spectrum 
NAFLD covers a spectrum of disorders ranging from simple steatosis (non-alcoholic fatty 
liver, NAFL) to non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis (1, 47). 
Steatosis is defined as a condition where the percentage of hepatocytes with macroscopic 
steatosis when examined by histology exceeds 5-10% (48). When measured by proton 
magnetic resonance spectroscopy (1H-MRS), the upper limit of normal was 5.56% in the 
population-based Dallas Heart Study. This limit corresponded to the 95th percentile of liver 
triglycerides in subjects (n=345) without excess alcohol consumption, elevated S-ALT or 
abnormal fasting glucose (49). Liver steatosis is defined as non-alcoholic when it is not due 
to excess alcohol consumption (daily alcohol intake of <20 g for women and <30 g for men, 
(50)) or other known causes of steatosis such as hepatitis B and C, toxic, autoimmune, or 
drug-induced causes, Wilson’s disease, or hypolipobetaproteinemia (51).  
NASH is a pattern of injury in NAFLD and is distinguished from steatosis, or steatosis with 
mild inflammation by lobular inflammation and hepatocyte ballooning (see Section 4.1.). 
Fibrosis is not required for the diagnosis of NASH, although it is often present (52, 53). 
2.2 Natural course 
Simple steatosis has been thought of as more of a benign condition, but this view has been 
recently challenged, as paired biopsy studies have shown that NAFL can progress to NASH 
and fibrosis (54). 
In a Chinese prospective multicentre study, including 52 biopsied NAFLD patients, after a 3 
year follow-up, of the 13 patients with simple steatosis at baseline, 15% had normal liver, 
23% continued to have steatosis, 39% developed borderline NASH, and 23% developed 
NASH (55). Among those with NASH at baseline (n=17), only one patient (6%) regressed to 
simple steatosis. There was no significant change in anthropometric parameters and lipid 
profile in the follow-up (55). In another study with paired biopsies (n=40), after a median 11 
year interval, none had developed NASH (56). In 108 biopsied patients referred to a tertiary 
NAFLD clinic, during a median of 7-year follow-up progression to NASH was seen in 44% 
of patients with baseline NAFL (54). In this cohort, the BMI had also significantly increased 
and patients were more likely to have diabetes (54). In 106 NASH patients with paired-
biopsies, after a median of 4.3 years one-third showed progression of fibrosis (57). 
NAFLD increases the risk of hepatocellular carcinoma (HCC) (48). This occurs especially in 
patients who have developed liver cirrhosis (58), but cirrhosis is not necessary for HCC to 
develop. The yearly risk of progression from the final stage of fibrosis (stage 4, cirrhosis) into 
HCC is 2-3% (59). Worryingly, a study in 49 biopsied HCC patients showed that simple 
steatosis may also progress to HCC without cirrhosis (60).  
2.3. Epidemiology 
2.3.1 NAFLD  
NAFLD is the leading cause of chronic liver disease in the Western world (61), and it is 
projected to soon become the leading cause of liver transplantation (62). 
Prevalence estimates of NAFLD based on measurement of liver fat content vary depending 
on the population examined (i.e. ethnicity, sex, comorbidities) and the sensitivity of the 
diagnostic test applied (63). Using 1H-MRS in an unselected population of 2,339 U.S. adults 
in the Dallas Heart Study, one-third (31%) were found to have hepatic steatosis. Ultrasound 
studies assessing steatosis in Europe have shown the prevalence to range between 20% and 
33% (64-66).  
Biopsy-based studies in healthy living liver donors showed the prevalence of simple steatosis 
(NAFL) to be 12-37% in Europe (67, 68) and 26-31% in the U.S. (69, 70). A post-mortem 
biopsy study in an unselected population of 498 subjects aged 3-94 years in Greece revealed 
NAFL in 31% (71).  
A large meta-analysis based on imaging of steatosis found the prevalence of NAFLD to be 
23% in Europe, 24% in North America, 30% in South America, 32% in the Middle East, 27% 
in Asia, and 13% in Africa (12). In the same meta-analysis, the pooled global prevalence of 
NAFLD was estimated to be 25% (12). 
Prevalence of NAFLD in relation to metabolic risk factors 
In patients with NAFLD, the most common cause of death is cardiovascular disease (CVD) 
(72, 73). The rate of CVD mortality in subjects with NAFLD is approximately 2-fold higher 
than in those without NAFLD (74). In addition, liver-related mortality is up to six times as 
common in patients with NASH than in non-NASH subjects (73, 75). 
The prevalence of metabolic risk factors is greatly increased in NAFLD. In the DIONYSOS 
study, NAFLD diagnosed by ultrasound (US) was present in 94% of obese (BMI>30 kg/m2), 
in 67% of overweight (BMI 25.0-29.9 kg/m2), and in 25% of normal-weight subjects (BMI 
20.0-24.9 kg/m2) (76). In severely obese subjects, the prevalence is even higher, 85-98%, in 
studies based on liver biopsy (77-80). Similarly, patients with type 2 diabetes (DM2) have a 
much greater overall prevalence of NAFLD (40-70%) than the general population (81-85). A 
recent study in 100 DM2 patients, in which NAFLD was measured using 1H-MRI and 
fibrosis by magnetic resonance elastography (MRE) found the prevalence of NAFLD to be 
65% and that of advanced fibrosis 7% (86). 
2.3.2 Non-alcoholic steatohepatitis (NASH) 
Biopsy is the golden standard in distinguishing between simple steatosis and NASH, and thus 
the current NASH prevalence estimates rely largely on selected groups of biopsied subjects. 
In a study with biopsies taken because of elevated transaminases due to unknown causes 
NASH prevalence was found to be 16% (87). In healthy liver donors, the corresponding 
proportion was 6-15% (67, 70). In subjects who had fatty liver based on ultrasound, NASH 
was found in 30% (85, 88). An earlier (1990) autopsy study in Canada found the prevalence 
of NASH to be 3% (89), while a post-mortem study in Greece found NASH in 40% of 
subjects (71). In the latter study, nevertheless, the patients had a mean age of 65 years and 
had metabolic comorbidities (half of them died of coronary artery disease). Alarmingly, in 
patients evaluated for liver transplantation, the prevalence of NASH showed an 8-fold 
increase from 1.2% to 9.7% in just ten years (90, 91). A systematic review from 2011 
estimated the prevalence of NASH to be 3-5% (58). There are, however, no population-based 
estimates of the prevalence of NASH. 
Prevalence of NASH in relation to metabolic risk factors 
In the aforementioned Canadian autopsy study, NASH prevalence was found to be 18.5% in 
markedly obese subjects, and a history of type 2 diabetes (DM2) was associated with a 2.6-
fold increase in NASH (89). NASH is estimated to be present in 25-30% of obese or diabetic 
patients, and in 35% of severely obese patients with DM2 (92-94). In patients biopsied during 
bariatric surgery, the prevalence estimates of NASH have ranged from 23% to 56% (79, 80, 
95-97). 
A pooled overall NASH prevalence estimate in a meta-analysis of biopsied NAFLD subjects 
was 59%. The pooled regional NASH prevalence estimates in NAFLD patients with an 
indication for biopsy were 63% for Asia, 69% for Europe, and 60% for North America (12).   
Fibrosis 
NASH affects progression of fibrosis. In a meta-analysis, liver fibrosis progressed by one 
stage over 14 years in patients with NAFLD and by the same amount in only 7 years in 
patients with NASH (98). Diabetes increases the risk of fibrosis development (54), as does 
older age and metabolic abnormalities (56). A recent study examining the changes in 
prevalence of hepatitis C (HCV), NASH, and alcoholic liver disease (ALD) among patients 
with cirrhosis or liver failure from three different databases (NHANES, HealthCare 
Integrated Research database, UNOS, between the years 2003 and 2015) found decreases in 
percentages of patients with compensated cirrhosis from HCV or ALD, but an increase in 
percentages or patients with cirrhosis from NASH (99). A similar trend was seen in chronic 
liver failure (CLF), with an almost 3-fold increase in proportion of patients with CLF from 
NASH (99). This increase indeed parallels the increase in prevalence of obesity. 
HCC 
NAFLD has been suggested to have become the most common liver disease associated with 
HCC. In 2010, NAFLD was the most common (35%) cause of referral to the hepatology 
clinic amongst patients with HCC (100). Obesity (101) and diabetes (102) are also known 
risk factors for HCC.  
There is a worrying trend in the incidence of HCC. In the U.S., the number of cases with 
HCC increased by 115% in just 12 years (2000-2012) and the age-adjusted incidence 
increased 1.5-fold from 4.4/100 000 in 2000 to 6.7/100 000 in 2012 (103). In the past 50 
years, the age-adjusted incidence of HCC in Finland has increased 5-fold in men and 2-fold 
in women (104). 
2.4 Risk factors 
 
2.4.1 Age, gender, and ethnicity 
NAFLD increases with age (105, 106). Age together with metabolic risk factors identifies 
patients with NASH who are at a high risk of advanced liver fibrosis (107, 108). 
Nevertheless, the higher prevalence and disease severity could be a result of a cumulative 
effect of longer duration of NAFL/NASH and an increase in the prevalence of components of 
metabolic syndrome. 
Gender. Available data on the role of gender in predisposition for NAFLD is conflicting. 
Although earlier reports suggested NAFLD to be more prevalent in women than in men (95, 
109, 110), several more recent studies have found the opposite (65, 85, 106). Consistent with 
these studies, men have more intra-abdominal and liver fat than women with the same BMI 
(2, 111). 
Ethnicity. The role of ethnicity in NAFLD is well established. In the U.S., NAFLD was found 
to be most common in Hispanics (45%), followed by European Americans (33%) and lastly 
African Americans (24%) (112). This finding has been supported by a recent large study (N = 
9675) on the racial differences in NAFLD (113), as well as a large meta-analysis (12). 
Hispanics also have a higher prevalence of NASH and cirrhosis than other ethnic groups, 
whereas African Americans are less likely to develop liver failure (114). 
As the racial variations can only partly be explained by the differences in ethnic lifestyle the 
role of genetic predisposition is suggested. This is supported by a study in which the 
PNPLA3-I148M allele was predominant in Hispanics, the group most prone to developing 
NAFLD (6). 
2.4.2 Obesity, metabolic syndrome and type 2 diabetes 
Obesity. Increasing obesity parallels the incremental burden of NAFLD, especially in the 
Western countries, and it is the most important risk factor for NAFLD (77, 115). In the U.S., 
more than one-third of the population is obese (116) and roughly the same proportion has 
NAFLD (112). BMI and waist circumference both positively correlate with the presence of 
NAFLD (117). Nevertheless, NAFLD can be present in individuals with normal BMI and 
without metabolic risk factors (85, 118). 
Metabolic syndrome. The liver, once fatty and insulin-resistant, overproduces components of 
metabolic syndrome (112, 119, 120), which is why the conditions are tightly interrelated and 
NAFLD is sometimes referred to as the hepatic manifestation of metabolic syndrome (121). 
Like metabolic syndrome, NAFLD also increases the risk of both type 2 diabetes and 
cardiovascular disease (122). 
Type 2 diabetes. Several longitudinal studies have shown NAFLD to predict type 2 diabetes 
(74), and patients with type 2 diabetes are strongly predisposed to NAFLD (82, 84).  This 
association is observed even in the absence of obesity (119). Type 2 diabetes has been 
suggested to be a key factor in the progression of NAFLD to NASH, fibrosis and HCC (102, 
123, 124).  
2.4.3. Dietary factors and exercise  
Diet. There is a lack of long-term intervention studies comparing effects of diet on NAFLD, 
but based on the available knowledge some conclusions are justified.  
Hypocaloric diets decrease and caloric excess increase liver fat content (125). Low-fat and 
high-carbohydrate diets seem to decrease liver fat relative to high-fat and low-carbohydrate 
diets of similar caloric intake (126-128). The negative effect of high-fat diets appears to be 
due to SAFA (129). On the contrary, PUFA or MUFA diets may be beneficial (130, 131). A 
recent meta-analysis on the effect of different amounts of dietary fructose on the prevalence 
of NAFLD concluded that the harmful effect of fructose might be attributed to high calorie 
intake (132). 
Exercise. The benefit of exercise is unquestionable in NAFLD patients. Both aerobic and 
resistance exercise can improve NAFLD (133-136), even in the absence of significant weight 
loss (137). NAFLD is also associated with a low level of physical activity (138). A very 
recent systematic review comparing the benefits of resistance training with aerobic training in 
NAFLD patients found both to be effective in improving hepatic steatosis (139). The writers 
summarized the median effective exercise protocols to be moderate (4.8 METs) aerobic 
training sessions of 40 min/session 3 times a week, and for resistance training 3.5 METs for 
45 min/session 3 times a week (139). The latter is in concordance with the EASL-EASD-
EASO clinical practice guidelines  (47). 
  
2.4.4 Genetics 
There is a substantial heritable component to NAFLD across all ancestries (140). In 
individuals with Hispanic ancestry, the heritability of population-based NAFLD was found to 
be between 31% and 38% (141, 142). In three European ancestry family-based studies 
(Family Heart Study, The Old Order Amish, and the Framingham Heart Study), heritability 
was calculated to range from 26% to 27%. A population-based twin study in Finland suggests 
approximately 60% of the variation in ALT is genetically determined (143). In a U.S. cohort 
of 60 pairs of twins, the heritability of hepatic steatosis was 52%, and that of fibrosis 50% 
(144). 
Also, the difference in NAFLD prevalence in different regions can only partially be 
explained by differences in e.g. obesity, suggesting genetic differences in the predisposition 
to develop fatty liver (6, 145). As discussed above, NAFLD correlates with metabolic 
abnormalities, but imperfectly so (146). 
2.4.4.1 GWAS 
To identify specific genetic factors that are associated with NAFLD, several genome-wide 
association studies (GWAS) have been carried out. The first exome analysis of hepatic 
steatosis measured by 1H-MRS was performed in 2008 by Romeo et al. (6)  who found that a 
variant in the PNPLA3 gene, the G-allele at rs738409, encoding an I148M missense 
mutation, markedly and highly significantly contributed to increased liver fat content across 
several ethnic groups in the U.S. The same study, together with a more recent one (145), 
found that the difference in frequency of the PNPLA3 effect allele across ancestries 
accounted for more than 70% of the global variation in the prevalence of NAFLD (6, 145). 
Subsequent studies have replicated the association of the same variant not only with hepatic 
steatosis, but also with increased ALT activities (8, 147-149), steatosis diagnosed by imaging 
techniques (150-152), and abnormal liver histology, including steatosis, NASH, and 
fibrosis/cirrhosis (4, 7, 9, 151, 153, 154). A recent meta-analysis of almost 3000 
histologically determined NAFLD subjects showed that individuals homozygous for the 
PNPLA3 gene variant had 73% higher liver fat content, 3.24-fold greater risk of 
necroinflammatory scores, 3.2-fold greater risk of developing fibrosis, and 3.44 higher odds 
of developing NASH than those lacking the gene variant (155). 
The search for genetic factors underlying NAFLD is ongoing and various candidate genes in 
addition to PNPLA3 have been described. One of the largest GWAS studies using computer 
tomography (CT) to diagnose NAFLD (n=7176) and ~2.4 million SNPs suggested that 
additional variants in or near PNPLA3, NCAN/TM6SF2, LYPLAL1, GCKR and PPP1R3B 
genes influence liver fat content (151). These top variants associated with steatosis were 
assessed for their effects on 592 cases of biopsy proven NASH/fibrosis, and all of the 
variants except PPP1R3B were also found to be associated with progression of the disease 
(151). The association of the variants TM6SF2 and GCKR with NAFLD has been confirmed 
by subsequent independent studies (156-158). 
One of the most recent genes to be discovered in 2015 was a variant in membrane-bound O-
acyltransferase domain containing 7 (MBOAT7) at rs641738 (159). It was shown to increase 
the risk of alcohol-related cirrhosis (159) and has since been additionally shown to increase 
the risk of steatosis and histologic liver damage in NAFLD, independent of obesity (160).  
 
2.4.4.2 PNPLA3 
The PNPLA3 gene resides on chromosome 22 and stands for patatin-like phospholipase 
domain-containing protein 3, also called adiponutrin. In 2008, a single-nucleotide 
polymorphism (SNP) at rs738409 was found to cause a substitution from cytosine (C) to 
guanine (G), resulting in a switch from isoleucine to methionine at position 148 (I148M) (6). 
This variant has since been associated with liver fat and progressive liver disease (see below).  
PNPLA3 gene encodes for a protein that relates structurally to the principal TAG hydrolase in 
adipose tissue, adipose tissue triglyceride lipase (ATGL/PNPLA2) (161, 162). In humans, it 
is predominantly expressed in the liver and distributed between membranes and lipid droplets 
(163). In vitro studies have demonstrated the wild-type enzyme to have hydrolytic (lipolytic) 
activity against three major glycerolipids (tri-, di-, and monoacylglycerides), with a strong 
preference for those with oleic acid (C18:1) as their acyl moiety (164, 165). The I148M 
amino acid substitution affects the lipophilic substrate-binding site of the hydrolase, and thus, 
may prevent the binding of substrates to the catalytic site (165). Tracer studies and in vitro 
models have demonstrated reduced VLDL-TAG secretion in the I148M carriers, which could 
suggest failure to mobilize TAGs from intracellular droplets due to the diminished hydrolase 
action i.e. loss-of-function (166). This model has nevertheless been challenged by, for 
example, the finding that deletion of pnpla3 in mice did not initiate hepatic steatosis (167). 
In line with the latter, in addition to lipase activity, PNPLA3 has been demonstrated to exhibit 
lysophosphatidic acid acyltransferase (LPAAT) activity, which promotes intracellular lipid 
synthesis by converting LPA to phosphatidic acid (168). In accordance with this, the human 
I148M rs738409 variant had increased LPAAT activity (168). This gain-of-function mutation 
causing increased intracellular lipid synthesis is an additional suggested mechanism for 
hepatic lipid accumulation in the variant carriers (168). Further studies have confirmed that 
overexpression of the PNPLA3 I148M exclusively in the liver leads to hepatic steatosis, with 
three notable metabolic effects: increased synthesis of FAs and TAGs, reduced TAG 
hydrolysis, and relative depletion of TAG long-chain PUFAs (169). 
Mice studies have shown that the metabolic milieu may affect PNPLA3 expression, which is 
reduced by fasting and increased after feeding (170, 171). Postprandial PNPLA3 expression 
is controlled by insulin via liver X-receptor-retinoid X-receptor (LXR-RXR) and sterol 
regulatory element-binding protein 1 (SREBP-1), and additional posttranslational control is 
provided by specific FAs (such as palmitate C16:0, oleic acid C18:1, linoleic acid C18:2) by 
increasing PNPLA3 expression (163). 
PNPLA3 and the spectrum of NAFLD 
Due to the implication that PNPLA3 mutation is a possible modifier of NAFLD pathogenesis, 
the polymorphism has been extensively studied and its association with the accumulation of 
liver fat independently confirmed in numerous candidate gene studies (5, 7-9, 154). Also, an 
association with elevated AST and ALT levels has been established (152), and there is 
increasing evidence that the rs738409 (I148M) variant is associated with more severe NASH 
and greater fibrosis (7, 9, 154), as well as an increased risk of HCC (172, 173). Curiously, 
NAFLD patients with the PNPLA3 mutation (“PNPLA3 NAFLD”) present with less 
metabolic abnormalities, such as hyperglycemia, hypertriglyceridemia, and low HDL 
cholesterol concentration, than NAFLD patients with the wild-type PNPLA3 
(“obese/metabolic NAFLD”) (3). Additionally, ‘PNPLA3 NAFLD’ dissociates from insulin 
resistance (8) and type 2 diabetes (6), and seems to be more susceptible to a weight loss-
induced decrease of hepatic fat (174-176). These latter findings support NAFLD aetiology as 
heterogeneous and the existence of NAFLD subtypes. 
Prevalence of PNPLA3 variant 
The prevalence of PNPLA3 rs738409 is dependent on the population studied. In Western 
populations, the prevalence of the heterozygous (CG) gene variant is 35-42% and the 
homozygous (GG) gene variant about 5% (177).  In Finland, the prevalence of the CG variant 
is around 36% and that of the GG around 6% (5).  
2.4.4.3 TM6SF2 
After the current studies, an exome-wide association study in over 2700 subjects identified a 
nonsynonymous SNP (rs58542926) in the TM6SF2 gene to be associated with fatty liver 
disease (156). Subsequently, the E167K variant has been robustly associated with steatosis, 
NASH, and advanced fibrosis/cirrhosis (151, 156, 178-182). 
 
Transmembrane 6 superfamily member 2 (TM6SF2) is a gene encoding a 351 amino acid 
protein with hitherto unknown function (182). It is expressed predominantly in the liver and 
intestine (182). The TM6SF2 rs58542926 variant is characterized by a C-to-T substitution in 
nucleotide 499, encoding a glutamate to lysine substitution at codon 167 (E167K).  In vitro 
(156, 180, 182) and in vivo (179, 180) studies suggest that the TM6SF2 gene mutation or 
deletion results in reduction of lipoprotein secretion (VLDL, TAG, and apoB) with a 
corresponding increase in hepatocellular lipid droplet size and TAG content.  
 
The TM6SF2 rs58542926 variant provides new insight into the pathogenesis of NAFLD and 
into the association between NALFD and cardiovascular disease. The metabolic effect of the 
mutation suggests that the TM6SF2 could act as a ‘switch’: the rs58542926 T-allele causes 
hepatic retention of TAG and cholesterol, predisposing its carriers to NAFLD fibrosis, 
whereas the C-allele (wild-type) is liver protective by promoting VLDL excretion, but at the 
cost of increased risk of cardiovascular disease (140).  
 
The prevalence estimate of the minor allele is 7% in Europeans, 5% in Hispanic Americans, 
and 3% in Africans (156). 
 
 
3. Pathogenesis of NAFLD 
Circulating lipids. The circulatory FFA pool represents a major source of hepatic fat 
accumulation in NAFLD patients. Due to the inhibitory action of insulin on lipolysis, FFA 
concentrations are lower after eating and high during fasting. When adipose tissue becomes 
insulin-resistant (IR), it also becomes resistant to the anti-lipolytic effect of insulin, resulting 
in high FFA concentrations despite high insulin concentration (183, 184). The circulating 
FFAs are reabsorbed by various organs (adipose tissue, liver, muscle) and some will be 
oxidized, whereas the remaining FFAs will accumulate as intracellular TAG droplets and 
lipid intermediates (such as DAGs and ceramides). The efflux of lipids from the liver 
happens via TAG-VLDL, which results in lowering of HDL cholesterol and an increased risk 
of atherosclerosis (185). 
Pathways of intrahepatocellular triglyceride synthesis. Studies using stable isotopes have 
shown the majority of liver fat to be derived from the circulating FFA pool (59%), and the 
rest to originate from increased DNL (26% in fatty liver vs. ~5% in normal-weight subjects), 
as well as dietary FAs (15%) (24). The development of peripheral insulin resistance results in 
failure of insulin to inhibit release of FFA from adipose tissue, leading to increased FFA 
delivery to the liver (186, 187). Hyperinsulinemia also stimulates DNL via stimulation of 
regulatory transcription factors (SREBP-1c and ChREBP) (188). Lack of insulin inhibition of 
gluconeogenesis is also responsible for increased DNL, as more metabolites are directed to 
DNL instead of glucose production, at least in mice (189).  
Mechanisms of lipid-induced insulin resistance. FFAs promote insulin resistance via 
substrate competition (190) and by inhibiting insulin signalling pathways. The latter occurs 
via bioactive lipids such as ceramides (191) and diacylglycerols. Ceramides are formed from 
saturated fatty acids and inhibit insulin-induced Akt/PKB phosphorylation (192). They also 
induce ER and oxidative stress (192) and are proinflammatory via activation of the c-Jun N-
terminal kinase (JNK) pathway, which induces hepatic fat accumulation and insulin 
resistance in mice (192). We recently showed increased hepatic ceramides, saturated TAGs 
and FFA characterize the liver lipidome in obese NAFLD (11). They also activate pro-
inflammatory M1-macrophages (193). DAGs have been suggested to cause lipid-induced 
insulin resistance via PKC-ε-mediated insulin receptor Thr160 phosphorylation (194).  
 
3.1 NAFLD 
3.1.1 ‘Obese/metabolic NAFLD’ 
Obesity is common in metabolic syndrome and NAFLD, even though both can exist in non-
obese individuals. Metabolic syndrome (MetS) develops especially in those obese individuals 
with accumulation of fat in the liver (‘obese NAFLD’) (Fig. 1). Insulin resistance is the 
hallmark of this type of NAFLD, leading to hyperglycemia, hyperinsulinemia, increased 
production of VLDL and serum TAGs, which lowers HDL cholesterol (3). DNL is similarly 
increased in hyperinsulinemic subjects, as the stimulatory effect of insulin on DNL remains 
insulin-sensitive (195). Caloric excess due to overeating increases hepatic FA influx via 
peripheral lipolysis and hepatic lipogenesis, resulting in a fatty liver. 
Adipose tissue. Adipose tissue of ‘obese NAFLD’ individuals show several changes, 
including hypoxia (196), increased infiltration of macrophages surrounding dead adipocytes, 
and expression of chemokines and proinflammatory cytokines (197). Inflamed adipose tissue 
is insulin-resistant, leading to increased lipolysis and FFA flux to the liver (198). There is 
also a deficiency of the insulin-sensitizing and anti-inflammatory molecule adiponectin, 
which could contribute to fat accumulation in the liver and induce hepatic inflammation and 
insulin resistance (199). Adiponectin deficiency also contributes to increased ceramide 
concentrations by impairing their degradation (192). 
Gut-liver axis. A relatively new area of research is investigation of the role of gut microbiota 
and its changes in both obesity and NAFLD (200). Altered permeability of the intestinal 
mucosa to inflammatory mediators, such as endotoxin, is hypothesized to have a role in 
NAFLD pathogenesis. 
3.1.2 ‘PNPLA3 NAFLD’ 
In contrast to ‘obese NAFLD’, metabolic abnormalities do not on average characterize 
NAFLD associated with PNPLA3 rs738409 (‘PNPLA3 NAFLD’) (Fig. 1). Thus, as discussed 
earlier (Review of the Literature, Section 2.4.4.2 PNPLA3), ‘PNPLA3 NAFLD’ is not 
accompanied by insulin resistance, hyperglycemia, hypertriglyceridemia and low HDL 
cholesterol (5, 6, 151, 201-204), or inflammation in adipose tissue (205). Unlike previous 
studies that have shown PNPLA3 mutation to increase liver fat, whilst having no effect on 
body weight, a recent study by Park et al. (206) showed liver fat to differ between individuals 
with different PNPLA3 genotypes (wild-type vs. mutation) but similar BMI. In fact, when 
adjusting BMI with liver fat in the groups with different genotypes, carriers of the gene 
variant (‘PNPLA3 NAFLD’) were leaner than those in which NAFLD was due to obesity 
(‘obese NAFLD’) (207). 
The mechanism behind the PNPLA3 I148M variant induced liver fat accumulation has been 
discussed in more detail in Section 2.4.4.2 PNPLA3. Studies in mice have shown 
overexpression of the human PNPLA3 I148M variant exclusively in the liver to cause hepatic 
TAG accumulation (169). Overexpression of the same variant in adipose tissue had no effect 
on liver fat content, body weight, fat distribution, or adipose tissue TAG content, morphology 
or gene expression (169). Individuals homozygous (GG) to I148M variant allele show a 
lower rate of DNL (which produces IR-inducing SAFAs) than those without the gene variant 
(208). In contrast to ‘obese NAFLD’, where there is an increase in hepatic ceramides, 
saturated TAGs, and FFA, the ‘PNPLA3 NAFLD’ predominantly contains an excess of 
polyunsaturated TAGs, with no changes in FFA (11). In vitro studies have found the I148M 
gene variant to decrease the rate of lipolysis of intrahepatocellular TAG (169), whereas 
subsequent studies found the mutation to increase TAG synthesis (168). In line with the gain-
of-function theory, a recent study by Luukkonen et al. (11) found an increase in hepatic 
polyunsaturated TAGs and DAGs in the I148M variant allele carriers. Nevertheless, our 
current understanding of whether the I148M PNPLA3 variant inhibits TAG lipolysis or 
stimulates TAG synthesis or both is still limited and conclusions require further research. 
Figure 1.  
                





















’, caloric excess from
 overeating increases hepatic FA
 influx via peripheral lipolysis and hepatic lipogenesis, leading to fat 
accum
ulation in the liver. The liver in this type of N
A
FLD
 is insulin-resistant, causing m
etabolic abnorm
alities and increasing the risk of 
cardiovascular disease and type 2 diabetes. O







pairs hepatic lipolysis and/or 
increases lipogenesis, leading to hepatic steatosis w
ithout causing insulin resistance or increasing the risk of cardiovascular disease or type 2 
diabetes.
 3.2. NASH 
In NAFLD, accumulation of TAGs in hepatocytes could be viewed as an early adaptive 
response to convert potentially lipotoxic FFAs into metabolically inert TAGs (210). 
Increased DNL promotes accumulation of lipotoxic intermediates, such as DAGs and 
ceramides, which cause IR (192, 211).  Increased FFA influx, together with reduced TAG 
efflux from the liver is believed to overpower the adaptive mechanisms promoting hepatocyte 
lipotoxicity, generation of reactive oxygen species (ROS), and endoplasmic reticulum ER 
stress (74, 212). These disturbances combine with the harmful effect of cytokine release by 
Kuppfer cells and immune-mediated cellular injury (213-215) . Kuppfer cells are resident 
macrophages that release cytokines, such as IL-1β and TNF-α, in response to messages from 
injured cells and TLR4, leading to inflammasome activation (216-219). Hepatocellular 
damage and stimulation of cell death pathways mark the transition to steatohepatitis (NASH). 
It remains unclear why some individuals but not others with simple steatosis develop NASH. 
Progression of NAFLD/NASH is likely to reflect the combined effect of several molecular 
and immunological processes and is a “multiple hits” rather than a “first hit – second hit” 
phenomenon. 
Lipotoxicity. Hepatic SAFAs are mainly derived from adipose tissue, the diet and de novo 
lipogenesis. Normally, SAFAs are transported to mitochondria for β-oxidation or esterified 
for either excretion in VLDL or storage as TAG. When the liver is overwhelmed by SAFA, 
multiple mechanisms could cause liver injury in hepatocytes (220). These lipids stimulate a 
variety of intracellular responses, especially formation of ceramides (11, 192), resulting in 
lipotoxic stress in the ER and mitochondria (221). Consequently, apoptosis occurs – a key 
pathogenic feature of NASH. 
Oxidative stress and mitochondrial dysfunction. FA oxidation in liver is the main source of 
ROS. Oxidative stress arises from an imbalance between production of ROS and that of 
antioxidants, and represents a common final pathway in FFA lipotoxicity (222). Normally, 
short-, medium-, and long-chain FAs undergo β-oxidation primarily in the mitochondria of 
the liver via the tricarboxylic acid (TCA) cycle (223). But when there is an excess of FFAs, 
minor pathways, such as β-oxidation in the peroxisome, and cytochrome-mediated ω-
oxidation in the ER, become relevant, leading to an increased production of hepatic ROS 
(223). In line with this, both peroxisomal β-oxidation and ω-oxidation of long-chain fatty 
acids are increased in NASH (224).  Oxidative stress results in nuclear and mitochondrial 
DNA damage, phospholipid membrane disruption by lipid peroxidation, and the release of 
proinflammatory cytokines (223). 
Switching from mitochondrial to peroxisomal/ER oxidation could be a result of 
mitochondrial dysfunction (225) or abnormal morphology (222). A recent study discovered 
mitochondrial function to be increased in obese individuals with or without fatty liver, 
relative to lean individuals, despite similar hepatic mitochondrial mass (226). On the other 
hand, individuals with NASH had higher mitochondrial mass, but up to 40% lower maximal 
respiratory function, than obese individuals with or without fatty liver (226). This indicates 
ability of mitochondria to adapt in the early stages of obesity and simple steatosis, which is 
subsequently lost in NASH.  
Endoplasmic reticulum stress. Lipid accumulation and impaired lipid oxidation can lead to 
dysfunction of the ER. The ER is a membranous intracellular network responsible for folding 
of majority of secreted and membrane proteins, synthesis of PLs, and functioning of 
enzymes, including cytochrome P450 (227, 228). Not only can obesity (229) and hepatic 
steatosis (230) induce ER stress, but experimental models have shown ER stress per se to be 
able to induce hepatic steatosis (231), as well as to inhibit VLDL secretion (232). Together 
these changes form a vicious circle of fat accumulation in the liver. 
ER stress may also lead to misfolding or unfolding of proteins. These proteins form 
aggregates triggering the unfolded protein response (UPR) pathway, which aims to re-
establish normal homeostasis by decreasing protein synthesis and ER-associated protein 
degradation (233). If this response is inadequate, stress sensor proteins, such as transcription 
factor 6 (TF-6) and inositol-requiring enzyme-1 (IRE-1) can trigger apoptosis (234, 235). 
Variable degrees of UPR activation are seen in both NAFLD and NASH (234). 
Other factors. In addition to the above-mentioned mechanisms, many additional “hits” have 
been identified to contribute to NASH pathogenesis. To name a few; innate immunity and 
gut-derived signals, with endotoxin (LPS) and TLR4 as important components, may promote 
NASH (223). Chemokines and their receptors, such as C-C chemokine receptor 2 and its 
ligand CCL2, act as major regulators of macrophages in liver during inflammation (236). 
Nuclear receptors, including liver X receptor (LXR), responsible for regulating cholesterol 
homeostasis (237), as well as bile acid metabolism-mediating farnesoid X receptor (FXR) 
have both been both associated with NASH pathogenesis (238). Autophagy, in which cell 
constituents are targeted to lysosomes for degradation, is linked to IR, hepatic injury, and 
fibrogenesis (207) and is suggested to be increased in NASH.  Other areas of interest include 
the role of microRNAs, metabolic hormone pathways, and intestinal microbiota in the 
progression of NAFLD/NASH.  
Hepatocyte injury and death. Ultimately, the “multiple hits” combine to cause cellular 
damage and induce cell death pathways. Breakdown of cellular components can occur either 
in a programmed manner with intact plasma membrane (apoptosis) or accidentally in a lytic 
and inflammatory process (necrosis). Apoptosis is highly regulated and is a prominent feature 
in NASH (239). Indeed, cleaved cytokeratin 18 fragments (CK18), markers of apoptotic 
activity, have been correlated with NAFLD disease severity (240). Additionally, death 
receptors responsible for initiating apoptosis, such as Fas and TNF-receptor1, are increased in 
livers of NASH patients (239, 241). These cell death pathways remain an intense area of 
research and could potentially be used as markers of disease progression in NAFLD. 
PNPLA3 and NASH. Previous studies have shown the I148M PNPLA3 variant to predispose 
to NASH independent of features of IR (155). In a recent study (11), subjects with ‘Metabolic 
NAFLD’ and ‘PNPLA3 NAFLD’ had an equal frequency of NASH despite different hepatic 
TAG and bioactive lipid compositions. Fat accumulation in the liver without hepatocellular 
injury predicts NASH (54), and thus, the PNPLA3 variant could simply increase the risk of 
NAFLD by increasing steatosis.   
 
On the other hand, PNPLA3 is highly expressed in human hepatic stellate cells (HSCs), and 
its expression seems to be regulated by retinol availability and insulin. Increased PNPLA3 
expression resulted in reduced lipid droplet content, whereas mutation in the PNPLA3 was 
accompanied by lower levels of retinol binding protein 4 (RBP4), indicating an intracellular 
retinol retention due to a loss-of-function in this PNPLA3 variant (242). Thus, possible links 








NAFL i.e. simple steatosis. Hepatic steatosis is defined as a condition where at least >5% of 
hepatocytes are lipid-filled (48) (Table 1). Steatosis in NAFLD is typically macrovesicular, in 
which a single or several well defined cytoplasmic lipid droplet(s) displace the nucleus to the 
cell periphery (243). Microvesicular steatosis, in which lipid droplets in the cytoplasm are 
minute and localized around a centrally placed nucleus, may also occur. A mixture of the two 
types, micro- and macrovesicular steatosis is often observed (243). Additionally, in simple 
steatosis foci of lobular inflammation, mild portal inflammation and lipogranulomas but not 
features of hepatocellular injury and fibrosis can also be seen (243). Fat accumulation tends 
to start in the acinar zone 3 i.e. in the perivenular area of the hepatocyte. Thus, the extent of 
steatosis is mainly evaluated from this area and graded as mild (0-33%), moderate (33-66%), 
or severe (>66 %). In severe steatosis, the whole acinus can be occupied (244). 
 
NASH. The minimal criteria to diagnose histological NASH include steatosis and hepatocyte 
injury, which usually presents as ballooning and lobular inflammation, typically also in 
acinar zone 3. Fibrosis is not necessary for diagnosis of NASH (53, 245) (Table 1). 
 
Ballooning degeneration i.e. presence of enlarged apoptotic hepatocytes, is the key feature 
for differentiating NAFL from NASH (246). Ballooning is graded as minimal (0), present (1), 
or marked (2).  
 
Lobular inflammation is usually mild, consisting of inflammatory cells, including 
lymphocytes, some eosinophils, and sometimes a few neutrophils. Diffuse lobular aggregates 
of Kuppfer cells i.e. microgranulomas and lipogranulomas, are common (247). Portal 
mononuclear cell infiltration is common and usually mild, and an increased portal 
inflammation is a marker of severe disease (248). 
 
Fibrosis is not required for the diagnosis of NASH, but its presence is not uncommon (Table 
1). Deposition of collagen and other extracellular matrix (ECM) fibres along the sinusoids of 
especially zone 3 and around the hepatocytes has a characteristic “chicken wire” pattern. In 
addition, portal fibrosis may occur, and in advanced disease, progression into bridging 
fibrosis and cirrhosis develops (244). Sinusoidal collagen formation in NASH is likely to be 
the result of hepatic stellate cell (HSC) activation (249, 250). Cirrhosis in NASH is usually 
macronodular or mixed, but not micronodular (243). 
 
Other histological lesions seen in NASH include Mallory-Denk bodies (MDBs) (251), which 
are associated with the severity of NASH (244) and strengthen the diagnosis, but are not 
specific to NASH (243). MDBs contain various misfolded proteins, including CK-18 (252). 
Other findings include megamitochondria, which could be a result of injury from lipid 
peroxidation or an adaptive change (253). Glycogenated, i.e. vacuolated nuclei support non-




The NAFLD activity score (NAS) was developed to diagnose NASH, originally in 
intervention studies, by combining histological evaluation of steatosis, ballooning and lobular 
inflammation  (255). NAS ≥5 is suggestive of NASH and < 3 the absence of NASH. Recent 
Table 1. Characterization of NAFLD spectrum of diseases. Adapted from Kleiner et al. 
(254). 
Histological diagnosis Definition 
Normal liver Less than 5% of hepatocytes steatotic and no other 
pathological changes (ballooning, fibrosis) that indicate 
NASH 
Simple steatosis (NAFL) 
• + inflammation 
• + nonspecific fibrosis 
Steatosis without ballooning or fibrosis 
Possible, non-uniform lobular inflammation and/or mild 
fibrosis of unknown importance 
NASH 
• Borderline NASH of zone 3 
Steatosis with zone 3 centred insult pattern including 
inflammation and ballooning necrosis (often with 
MDBs), with/without fibrosis. 
Borderline NASH has some, but not all of the 
characteristics required for diagnosis of NASH. 
Cryptogenic fibrosis/ cirrhosis Usually advanced fibrosis or cirrhosis, with/ without 
evidence of steatosis, and no evidence of 
borderline/definite NASH. 
studies have, however, questioned the benefit and prognostic value of the score (256-258). 
The latest studies support the grading of NAFLD by the SAF -score, in which S represents 
degree of steatosis (S0: <5%; S1: 5%-33%, S2: 34%-66%, S3: >67%), A the grade of activity 
(hepatocyte ballooning and activity of inflammatory cells; A0-A4), and F the grade of 
fibrosis (F0: none, F1: perisinusoidal, F2 perisinusoidal and periportal, F3: bridging fibrosis, 
F4: cirrhosis) (259). The inclusion of fibrosis is especially important, as it predicts both 
progression of NAFLD and mortality (72, 260). 
A liver biopsy is the only way to diagnose NASH but it cannot be used as a screening tool for 
population studies due to its high cost, and although a relatively safe procedure, it can have 
fatal complications, with a death rate of 0.01% (261). Limitations of the biopsy also include 
sampling error, as only 1/50 000-1/65 000 of the whole liver size is included, and thus, even a 
good-quality sample of approximately 10 portal tracts represents only a local process in the 
liver (244). As inflammatory lesions could be unevenly distributed in the liver, a biopsy may 
wrongly exclude NASH in up to one-third of the cases (262, 263). Additionally, inter- and 
intra-observer variability represents a serious problem (264), emphasizing the need for 
analysis by an experienced pathologist.  
 
4.2 Imaging tools  
 
Ultrasound (US) is a readily available tool for identification of steatosis and is the preferred 
method as a first-line diagnostic test, especially in tertiary settings. It has a sensitivity of 60-
94% and a specificity of 66-97% (265-267), but does not reliably detect steatosis when liver 
fat content is below 20% (268, 269) or in individuals with high body mass index (BMI 
>40 kg/m2) (70). Despite observer dependency, US robustly diagnoses moderate and severe 
steatosis and additionally provides important information on focal lesions and the 
hepatobiliary tract.  
 
Computer tomography (CT) detects fatty liver with a sensitivity of 93% (270) and like MRI, 
detects focal steatosis better than the US (271). Otherwise the US is more sensitive in 
diagnosing fatty liver disease (270, 271). However, due to the high radiation dose, CT cannot 
be used as a screening method (272). 
 
Magnetic resonance imaging and -spectroscopy (1H-MRI and 1H-MRS) are both non-
invasive, MR-based techniques that are used for determining liver fat content. Both 
techniques use the difference in resonance frequencies between water and fat proton signals 
to quantify the proton density fat fraction (PDFF) (273). PDFF reflects the fraction of mobile 
protons in liver due to fat. When measured correctly, PDFF is not affected by field strength, 
manufacturer, patient factors (age, sex, BMI, liver fat aetiology), or concomitant liver 
abnormalities, such as iron overload or necroinflammation (273). Currently, PDFF is the 
leading imaging-based biomarker of liver steatosis (273-276). 
 
1H-MRI can accurately detect liver steatosis of 3% (273) and is a good standard method for 
diagnosis of fatty liver. However, advances in the 1H-MRS technique have led to it becoming 
the golden standard (49); it may be even more reliable than biopsy, as it determines the whole 
liver volume (277). 1H-MRS measures a 3D metric of hepatic fat content, i.e. the TAG 
concentration in liver tissue (273), in contrast to histology, which evaluates the number of 
steatotic hepatocytes (277). Steatosis assessed by the 1H-MRS strongly correlates with liver 
biopsy based steatosis grading (278). Also, the sensitivity of 1H-MRS is excellent and it can 
detect even small amounts of TAGs, which might be missed on histological analysis (272). 
Nonetheless the use of 1H-MRS is still rather limited due to being expensive, not widely 
available on routine scanners, and requiring special coils and expertise to be used. Thus, the 
MRI-PDFF modality is currently better for assessment of liver steatosis. 
 
4.3 Circulating markers  
 
AST, ALT. NAFLD is the most common cause for elevated AST and/or ALT in population-
based studies in the U.S. (279) and Finland (280), although these enzymes are within the 
normal range in half of patients with NAFLD diagnosed by 1H-MRS (2). It is also not 
uncommon to find normal ALT and AST concentrations in patients with NASH or advanced 
cirrhosis (281). ALT is more liver-specific than AST, although the AST/ALT –ratio increases 
once NAFLD progresses. In a study with 238 biopsy-proven NAFLD cases, the area under 
the ROC-curve (AUROC) for ALT levels was 0.62 for diagnosing NASH (281). Higher cut-
off values (53-70 IU/L), as opposed to lower ones (<35 IU/L were more specific (51-61% vs. 
29%) but less sensitive (50-72% vs. 89%)) (281). Thus, abnormal liver function tests are 
neither sensitive nor specific markers of NAFLD. The AST to ALT ratio has also been used 
to differentiate between alcoholic and non-alcoholic steatohepatitis (282). Nonetheless, a 
population-based study in 2766 subjects showed no differences in ALT, AST concentrations, 
or AST/ALT ratio between NAFLD and AFLD (280). Alcohol consumption increases the 
gamma-GT concentration markedly and this enzyme reflects AFLD more than NAFLD 
(280). 
 
Markers of apoptosis. Cytokeratin 18 (CK18) is a major component of intermediate filaments 
of simple epithelial cells in the liver (283). Liver cell apoptosis is associated with collapse of 
the keratin cytoskeleton due to activation of intracellular proteases such as caspase-3 and 
caspase-7 (284), which cleave the intact CK-18 (M65 antigen) into three fragments, one of 
which is the M30 antigen (285). Both CK-18 and the M30 have been suggested to help in 
prediction of NASH in a meta-analysis (286), which reported a sensitivity of 83% and 
specificity of 71% for CK-18 M30 for diagnosis of NASH. The total CK-18 concentration 
had a sensitivity and specificity of 77% and 71%, respectively (286). Nevertheless, the 
sensitivity of CK-18 to distinguish NASH from NAFL has since been questioned (287). 
 
Markers of inflammation. Increased circulating concentrations of tumour necrosis factor 
alpha (TNF-α) have been associated with NASH, insulin resistance, and fibrosis (288-290). 
The concentrations of serum TNF-α and interleukin 6 (IL-6) were increased in NASH 
relative to NAFL (291). Additionally, many other cytokines, such as IL-B, macrophage 
inflammatory proteins, and adipokines, including adiponectin, leptin, resistin, visfatin, and 
retinol binding protein-4, have been studied as potential biomarkers, but the results have been 
inconsistent and limited by small sample sizes (292, 293). Use of serum ferritin (SF) has also 
been examined. In a biopsy cohort of 628 subjects, elevated SF (>1.5-fold increase above 
upper limit) was associated with NASH, and SF was independently associated with higher 
NAS (294). SF is, however, elevated in various chronic illnesses and inflammatory states and 
is thus likely to be a too non-specific marker for NASH. A very recent study on biomarkers 
of NASH and fibrosis in 648 biopsy-proven patients showed strong association of increased 
concentrations of activated plasminogen activator inhibitor 1 (aPAI1), a serine protease 
inhibitor, in subjects with NASH, relative to subjects without NASH or borderline NASH 
(295). 
 
Novel markers. UPLC-MS based techniques are increasingly replacing many traditional 
techniques in biomarker research (296). A study in which metabolomic analyses were 
performed in patients with histologically proven NASH (n=24) or NAFL (n=11) and normal 
subjects without liver biopsy (n=25) showed increased concentrations of five amino acids 
(297). The diagnostic performances of these were not compared to routinely available 
markers (297). Another study that analysed the lipid and metabolite profile of 467 biopsy 
proven patients found between 9 and 237 lipids/metabolites to be associated with NASH 
depending on BMI, suggesting that the degree of obesity influences the relationship between 
NASH and biomarker concentrations (298). This study also found decreased concentrations 
of serum PUFA containing TAGs in NASH patients (298). This is in line with the finding of 
increased absolute overproduction of MUFA and SAFA containing TAGs in the splanchnic 
area of subjects with NAFLD (299), as well as with a recent study showing absolute and 
relative excess of these same fatty acids in the circulating lipidome in NASH patients (300). 
 
A proof-of-concept study by Loomba et al. (301) of 19 biopsy proven NAFLD patients 
(NASH n=9, NAFL n=10) vs. 10 non-NAFLD MRI phenotyped controls showed that PUFA 
metabolites, especially arachidonic acid (AA) -derived eicosanoids differed between NAFL 
and NASH patients. The best single biomarker to differentiate between NAFL and NASH 
was 11,12-dihydroxy-eicosatrienoic acid (11, 12-diHETrE) with an AUROC of 1. However, 
the study was a small pilot study which needs to be validated (301).  
 
4.4 Risk scores 
NAFL. Various biomarker-based scores have been developed to diagnose steatosis. The 
SteatoTest uses a combination of FibroTest-Actitest plus BMI, serum cholesterol, TAG, and 
glucose adjusted by age and gender (302). The Fatty Liver Index (FLI) includes four 
variables, i.e. BMI, waist, TAG, and γGT (303). A simple index of lipid excess includes 
waist, TAG and gender (304). The Hepatic Steatosis Index contains AST/ALT ratio, BMI, 
and diabetes (305). To predict the presence of NAFLD, we developed the NAFLD liver fat 
score using metabolic syndrome, diabetes, insulin, AST, and AST/ALT ratio as the variables, 
and created a liver fat equation for prediction of the percentage of liver fat (306). Of novel 
markers, a recent study using UPLC-MS identified a “lipid triplet” to predict NAFLD with a 
sensitivity and specificity of 69% and 75% respectively. This test performed better than the 
Liver fat score or the SteatoTest (307). 
 
It has been argued that the scores themselves do not add much to the information provided by 
clinical, laboratory and imaging studies done routinely on patients with suspected NAFLD. 
On the other hand, in tertiary care settings where imaging modalities are not always 
available, the 2016 EASL-EASD-EASO Clinical Practice Guidelines encourage the use of 
serum biomarkers and scores, especially NAFLD Liver Fat Score, FLI, or SteatoTest® for 
diagnosis of NAFL.  
 
NASH. As the only reliable method currently available to diagnose NASH is the liver biopsy, 
there is a dire need for non-invasive methods.  At least 23 scores to predict NASH have been 
developed using routinely available clinical data as well as more specific variables, such as 
markers of inflammation, oxidative damage, and apoptosis (see Table 2). The NASH Test®, 
consisting of alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, total bilirubin, γGT, 
ALT, AST, TAGs, cholesterol, age, gender, height and weight, developed in France has been 
externally validated in other French cohorts, but it has a modest AUROC of 0.79 and a very 
limited sensitivity (308). The U.S. (50) and the European guidelines (47) recommended use 
of the NAFLD fibrosis score for diagnosis of fibrosis. The NICE guidelines recommended 
the use of Enhanced Liver Fibrosis® score (ELF®) for diagnosis of NASH  (309). The cost of 
these tests varies considerably (e.g. NAFLD fibrosis score 6 EUR, NASHTest® 44 EUR, 
ELF® 120 EUR). A promising novel score combining lipidomics, metabolomics and clinical 
markers was recently developed (300). 
 
Many of the currently available scores lack external validation, are based on a small sample 
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5. AIMS OF THE STUDY 
 
Studies I-III were performed to answer the following questions: 
 
A. Does the genetic variation in APOC3 contribute to liver fat content and plasma 
triglyceride and apoC3 concentrations? (I) 
 
B. What is the prevalence of NASH in Finnish subjects? (II) 
 
C. How does the PNPLA3 I148M gene variant influence circulating TAG 
concentrations? (III)  
 
6. STUDY SUBJECTS AND STUDY DESIGNS  
 
The subjects for the studies were recruited based on the following criteria, unless otherwise 
specified: (i) age 18-60 years; (ii) no known illness (acute or chronic) other than obesity or 
type 2 diabetes based on physical examination, ECG, and standard laboratory tests (blood 
counts, glucose, thyrotropin, serum creatinine, electrolytes); (iii) alcohol consumption less 
than 20g per day assessed by interview or questionnaire; (iv) no history of use of toxins or 
drugs known to induce hepatitis, no clinical signs of hepatitis A, B, or C, autoimmune 
hepatitis, or evidence of inborn errors of metabolism; (v) no medication that might affect 
glucose tolerance; and (vi) no pregnancy. Elevated liver enzymes (S-AST, S-ALT, S-γGT) 
did not exclude subjects.  
All subjects signed a written informed consent. The studies were performed according to the 
principles of the Declaration of Helsinki and approved by the Ethics Committee of Helsinki 
University Central Hospital. 
 
Study I.   
Objective: To determine whether the genetic variation in APOC3 contributes to liver fat 
content and plasma triglyceride and apoC3 concentrations. 
Subjects: For the NAFLD study, 417 Finns (310 non-diabetic and 107 type 2 diabetic) were 
recruited for metabolic studies by contacting occupational health services or by newspaper 
advertisements. Also, subjects referred to the Department of Gastroenterology because of 
elevated serum transaminase concentrations using the inclusion criteria as above were 
recruited. The patients have previously participated in metabolic studies (111, 328-330). 
Measurements and study design: 1H-MRS was used to measure liver fat content. NAFLD 
was defined as fat accumulation in the liver over 5.6% (55.6mg/g) when measured by 1H-
MRS. Plasma glucose, serum free insulin, fS-HDL, fS-TAG, fS-AST and fS-ALT 
concentrations were measured. PNPLA3 (rs738409) and APOC3 (rs2854116 and rs2854117) 
were genotyped using the TaqMan PCR method. Plasma apoC3 concentrations were 
measured enzymatically using ELISA. Metabolic syndrome was defined by using the IDF 
criteria.  
 
The subjects were genotyped for APOC3 and divided into wild-type homozygotes (T-455 and 
C482) and variant allele (T-455C at rs2854116, C-482T at rs2854117) carriers. The same was 
 
done for PNPLA3. The genotype groups were compared for clinical and biochemical 
characteristics, as well as for liver far content. 
 
Study II. 
Objective: To estimate non-invasively the prevalence of NASH  
Subjects: Biopsy subjects were recruited in Finland and Italy for discovery and validation of 
the ’NASH score’. The population-based FIN-D2D cohort was used to estimate the NASH 
prevalence using the ’NASH score’. 
 
Finnish biopsy cohort. Altogether 296 subjects from Helsinki (n=167) and Kuopio (n=129) 
eligible for laparoscopic gastric bypass operation were recruited to the study based on the 
aforementioned inclusion criteria. In addition to the standard laboratory tests outlined above, 
also serum CK-18 fragments were measured enzymatically using ELISA, and PNPLA3 was 
genotyped at rs 739409. Laboratory tests were performed one week before surgery after an 
overnight fast. Wedge biopsies of the liver were taken at surgery. 
 
Italian biopsy cohort. Altogether 380 subjects of Italian ancestry with a new diagnosis of 
NAFLD were followed at the Metabolic Liver Diseases outpatient service, Fondazione 
IRCCS Ca’ Granda Ospedale Policlinico. A liver biopsy was obtained from 309 subjects 
because of persistently abnormal liver enzymes/serum ferritin or a long-lasting history of 
steatosis with severe metabolic abnormalities. A total of 71 patients were recruited amongst 
patients eligible for bariatric surgery. Other causes of liver disease were excluded. Alcohol 
intake among subjects was <30 g/day for men and <20 g/day for women. 
 
FIN-D2D.  The study included 2849 patients chosen from a random sample of 4500 subjects 
aged 45-74 years selected from the National Population Register. The subjects were a part of 
the implementation project of the national type 2 diabetes prevention programme (FIN-D2D) 
(331). All subjects gave written consent, and the Ethics Committee of the Hospital District of 
Helsinki and Uusimaa approved the study protocol. All subjects received a self-administered 
questionnaire on health behaviour and medical history, together with an invitation to clinical 
examination. Men who consumed ≥ 40g and women ≥ 20g of alcohol were excluded from the 
NAFLD and NASH prevalence estimates. Body measurements were recorded at the site of 
the study. Glucose tolerance was classified according to WHO 1999 criteria (332). 
 
Laboratory tests (plasma glucose, serum insulin, serum total-, HDL-, and LDL cholesterol, 
triglyceride, serum ALT, AST and γGT concentrations) were performed. 
 
Measurements and study design. Clinical characteristics, PNPLA3 genotype (rs738409) and 
S-CK18 fragments were measured in 296 biopsy patients to construct (n=195) and validate 
(n=97) the ’NASH score’. Performance of the scores was analysed using the ROC-curve. The 
area under the ROC-curve (AUROC) was used to assess the diagnostic performance of the 
scores. Also, a cut-off for the diagnosis of NASH was defined for a previously validated 
NAFLD Liver Fat Score (306) (renamed ’NASH Liver Fat Score’). Both scores were 
validated in 380 Italian biopsy patients. The cut-offs were used in the population-based FIN-
D2D study of 2849 subjects aged 45-74 years to estimate the prevalence of NASH.  
 
Study III. 
Objective: To examine whether relative concentrations of circulating TAGs between carriers 
and non-carriers of PNPLA3 I148M gene mutation display deficiency of TAGs due to 
defective lipase activity in the liver. 
 
Subjects: Altogether 372 subjects were recruited by newspaper advertisement, contacting 
occupational health services or from patients referred to the Department of Gastroenterology 
due to chronically elevated liver enzymes using the aforementioned inclusion criteria. The 
study subjects have previously participated in metabolic studies (111, 328-330). 
 
Measurements and study design: A fasting blood sample was taken for measurement of fP-
glucose, fS-insulin, fS-LDL cholesterol, total serum cholesterol, fS-HDL cholesterol, fS-
TAG, fS-AST, fS-ALT and fS-γGT, as well as for lipidomic analyses. PNPLA3 was 
genotyped at rs739409. Height, weight, waist circumference and blood pressure were 
recorded. Liver fat content was measured by 1H-MRS in 75% of subjects and by liver biopsy 
in 25%. The degree of steatosis in the liver biopsy specimens was converted to liver fat 
percentage, as measured by 1H-MRS and liver histology, as previously described (333). 
NAFLD was defined as in Study I. Lipidomic analyses on serum and plasma samples were 
performed using Ultra-Performance Liquid Chromatography-Mass Spectometry (UPLC-MS). 
Metabolic syndrome was defined as described in Section 7, Methods. The subjects were 
divided into subgroups based on genotype (PNPLA3-I148M mutation carriers and wild-type 
carriers) and obesity. The groups with a BMI over the median BMI of 33.5 kg/m2 were 
 
referred to as ‘obese’, and the rest as ‘non-obese’. To determine whether obesity and the 
PNPLA3 I148M mutation are associated with differences in circulating TAGs in patients with 
similar liver fat content, we further divided subjects into those with NAFLD due to the 
PNPLA I148M variant (’PNPLA3 NAFLD’) and to those obese subjects with NAFLD who 




7.1 Anthropometric data (studies I, II, III) 
Body weight was recorded using a calibrated weighing scale with a 0.1 kg precision with 
subjects standing barefoot and wearing light indoor clothing. The waist circumference was 
measured midway between the spina iliaca superior and the margin of the lower rib. Body 
height was measured to the scale to the nearest 0.5 cm using a ruler attached. Blood pressure 
was recorded with a random-zero sphygmomanometer (ERKA, Bad Tölz, Germany) after 10-
15 minutes of rest with the subject sitting. 
 
7.2 Liver fat content   
Histology (studies II, III). A needle liver biopsy was taken under ultrasound guidance in 
patients with suspected NAFLD or in patients eligible for laparoscopic bypass operation. The 
liver samples included both core needle and conchotomy material. Liver histology was 
defined as previously described by Kleiner et al. (255). Both, NAFL and NASH subjects 
were included in the NAFLD group. Liver histology was assessed by two experienced 
pathologists in the Finnish cohorts in a blinded fashion, first independently and then together 
to obtain a consensus. In the Italian cohort, one experienced pathologists analysed the liver 
specimens.  Tissue sections were stained with haematoxylin and eosin and saturated with 
silver for reticulin framework. Trichome stain was used to expose collagen.  
 
1H-MRS (I, II, III). 1.5T scanners were used (Siemens Magnetom Vision, Erlangen, 
Germany) to acquire a localized single-voxel proton spectra, as previously described (334). 
Within the right liver lobe, T1-weighed MRI scans were used for localization of the voxel of 
interest, that was individually determined for each subject. A short echo time (20 ms) and 
long repetition time (3000 ms) were used to ensure a fully relaxed water signal. Water signal 
was used as an internal standard, relative to which the chemical shifts were measured at 
4.80ppm. The methylene signal, a representative of intracellular triglyceride, was measured at 
 
1.4ppm. The analysis program VAPRO-MRUI (http://www.mrui.uab.es/mrui) was used to 
quantify the signal intensities. The intracellular triglyceride content (steatosis) was presented 
as a ratio of the area under the methylene and water peaks multiplied by a 100 to obtain the 
liver fat percentage, which has been validated against histologically determined lipid content 
(335). NAFLD was defined as liver fat 55.6 mg triglyceride per gram of liver tissue or 5.56% 
of liver tissue weight (49). All image data were analysed by physicists who were unaware of 
the clinical data.  
 
7.3 Definition of metabolic syndrome, diabetes, and obesity (I, II, III) 
The Harmonization definition by the International Diabetes Federation was used to define 
metabolic syndrome (MetS) (332). Diabetes was defined by WHO’s criteria (336). 
Overweight was defined as BMI 25-29 kg/m2 and obesity as BMI ≥ 30 kg/m2.  
 
7.4 Analytical procedures 
Plasma glucose concentrations were analysed together with with the glucose oxidase method 
using Beckman Glucose Analyzer II (Beckman Instruments, Fullerton, CA, USA) (337) (I, II, 
III). Serum free insulin concentrations were measured using the auto-DELFIA kit (Wallac, 
Turku, Finland), and C-peptide by radioimmunoassay (338) (I, II, III). FS-triglyceride and fS-
HDL cholesterol concentrations were analysed using an autoanalyser with enzymatic kits 
from Roche Diagnostics (Roche Diagnostics Hitachi, Hitachi Ltd., Tokyo, Japan) (I, II, III). 
The Friedewald formula was used to determine the LDL cholesterol concentrations (339) (I, 
II, III). The activity levels of S-AST and S-ALT were analysed as recommended by the 
European Committee for Clinical Laboratory standards (I, II, III). Plasma ApoC3 
concentrations were measured enzymatically by AssayMax human Apolipoprotein C-III 
enzyme-linked immunoabsorbent assay (ELISA) kit (AssayPro, St. Charcles, MO, USA) (I). 
CK-18 M30 antibody fragments (U/L) were measured using Apoptosense® ELISA (cat. no. 
10010) assay (PEVIVA AB, Sweden) (II). 
 
For genotypic data, genomic DNA was extracted from whole blood as previously described 
(340). TaqMan polymerase chain reaction (PCR) method (Applied Biosystems, Foster City, 
CA, USA) was used to genotype PNPLA3 at rs738409 (I, II, III) and APOC3 at rs2854116 
and rs2854117 (I). ABI Prism Sequence Detection System ABI 7900HT (Applied 
Biosystems) was used to carry out post-PCR allelic discrimination (I, II, III).  
 
Lipidomic analyses on citrate plasma (78%) and EDTA plasma and serum (16% and 7%, 
respectively) samples were carried out using an established platform for ultra-performance 
liquid chromatography coupled to time-of-flight mass spectrometry (UPLC-MS), based on 
ACQUITY UPLC (Waters) (341). Studies comparing citrate and EDTA plasma and serum 
samples from the same subjects did not have statistically significant differences in the 
lipidomic data. In brief, 10 μL of serum or plasma sample was diluted with 10 μL of 0.15 M 
(0.9%) sodium chloride and 10 μL of internal standard mixture 1A was added, the mixture 
containing PC (17:0/0:0), PC (17:0/17:0), PE (17:0/17:0), PG (17:0/17:0) [rac], Cer 
(d18:1/17:0), PS (17:0/17:0) and PA (17:0/17:0) (Avanti Polar Lipids, Inc., Alabaster, AL, 
USA) and MAG (17:0/0:0/0:0) [rac], DAG (17:0/17:0/0:0) [rac] and TAG (17:0/17:0/17:0). 
The lipids are extracted using the mixture of HPLC-grade chloroform and methanol (2:1; 100 
μL). The lower phase (60 μL) was collected and 10 μL internal standard mixture 2 was 
added, containing labelled PC (16:1/0:0-D3), PC (16:1/16:1-D6), and TAG (16:0/16:0/16:0-
13C3). ESI+ mode was used to carry out lipid profiling and the data were collected at mass 
range of m/z 300-1200 with scan duration of 0.2 sec. MZmine 2 software (342) was used for 
data processing, and the identification of lipids was based on de novo identification using 
tandem mass spectroscopy (MS) or an internal spectral library (341). The data were 
normalized using one or more internal standards representative of each class of lipids present 
in the samples.  
 
7.5 Statistical analyses 
A p-value of less than 0.05 was considered statistically significant in all studies. Calculations 
were made using GraphPad Prism version 4.0 for Windows (GraphPad Software, San Diego, 
CA, USA) (I), Stata 9.2 (StataCorp, College Station, TX, USA) (I), SPSS 17.0 (I) or 19.0 (II) 
for Windows (SPSS, Chica§go, IL, USA), or the R 3.0.1 program (II, III). 
Study I.  
Kolmogorov-Smirnov test was used to test normality. Normally distributed data are reported 
as means ± SEM and non-normally distributed data as median (25% percentile, 75% 
percentile). Non-normally distributed data were analysed after logarithmic (base 10) 
transformation. Mann-Whitney test was used to compare the differences in liver fat and 
apoC3 concentration between variant-allele carriers and wild-type homozygotes. Kruskal-
Wallis test was used to compare haplotypes. Correlation analyses were carried out using 
Spearman’s non-parametric rank correlation coefficient. To compare differences in binary 
 
variables the Chi-squared test was used. One-way ANOVA was used to compare the 
genotypic effect on clinical variables and liver fat content. For post-hoc analysis the least 
significant difference pairwise multiple comparison test was used. Adjusting for use of 
confounders, such as statins, was carried out using analysis of covariance. The variance 
explained (%) by APOC3 and PNPLA3 genotypes was calculated with multiple linear 
regression analysis. 
 
Study II.  
Altogether 292 bariatric surgery patients with available required data were used to construct 
and validate a ‘NASH’ score. This was then used to estimate the prevalence of NASH in a 
population-based study of 2849 subjects aged 45-74 years. 
Development of the ‘NASH score’. The biopsy cohort was divided randomly into estimation 
group (n=195) to develop and validation group (n=97) to validate the model. A second 
validation group was built using all subjects (n=292). To compare the differences between 
the estimation and validation groups, the unpaired t-test was used. The odds ratio (OR) and 
confidence intervals (CIs) for NASH were calculated using the univariate logistic regression 
analyses. To identify variables that are independently associated with NASH, the variables 
that were significantly associated with NASH in univariate logistic regression analysis were 
included in multivariate backward logistic regression analyses. The ‘NASH score’ was then 
built using multivariate logistic regression analyses. The performance of the scores was 
assessed by the receiver operating characteristics (ROC) curve, and the diagnostic accuracy 
of the scores using area under the ROC-curve (AUROC). The Youden index was used to 
calculate the optimal cut-off point. The sensitivity (Se), specificity (Sp), negative predictive 
value (NPV), and positive predictive value (PPV) for the chosen cut-offs were calculated 
using formulas, as previously described (343). The 95% confidence interval (CI) for the 
NAFLD and NASH prevalences was calculated using the formula . 
‘NASH liver fat score’. For the ‘NALFD liver fat score’ equation, which had been developed 
to diagnose NAFLD, a new cut-off to diagnose NASH was calculated using ROC-curves and 
the Youden index. 
Sensitivity analyses. Sensitivity analyses were performed on the new ‘NASH score’ and the 
‘NASH liver fat score’ by assessing stochastic false-positivity and false-negativity rates in a 
Bayesian model. To construct the model JAGS and R-package were used on the basis of 2 
 
Markov chains, each containing 5000 “burn-in” samples and 10 000 retained samples to 
obtain the posterior estimates of the prevalence (344). 
 
Study III 
Division of subgroups. The study subjects were divided into groups based on either their 
genotype (PNPLA3 variant allele carriers [PNPLA3148MM/MI] vs. homozygotes [PNPLA3148II]) 
or obesity. The subjects with BMI over the median of 33.4 kg/m2 were referred to as the 
‘obese’ and those with BMI under the median BMI as ‘non-obese’. Subjects with liver 
steatosis due to the I148M variant were termed as ‘PNPLA3 NAFLD’, and  obese subjects 
without the I148M variant as ‘obese NAFLD’. 
Analysis of clinical data. Pearson Chi-squared test was used to determine the association of 
binary variables with PNPLA3 genotype or obesity. Shapiro-Wilks test was used to test for 
normality. To compare continuous values between the PNPLA3 variant and the wild-type and 
between obese and ‘non-obese’ groups, the Wilcoxon rank-sum test was applied. Medians 
and 95% CIs were calculated for non-normally distributed, and means and SEM for normally 
distributed data. 
Cluster analysis of lipidomics data. To group lipids with similar profiles in all study samples 
the Bayesian model-based clustering was applied using an R-package, mclust version 4.0. 
(345). Log2-tranformation was used on the lipidomics data and each lipid variable was scaled 
to zero mean and unit variance prior to analysis. For each resulting cluster an average profile 
was calculated by taking, sample by sample, the mean value of all variables in it. Students t-
test was used to compare the mean values of the cluster profiles between PNPLA3 variant and 
wild-type allele groups, and the obese vs. ‘non-obese’ groups.  
Analysis of TAG abundances. For all four subgroups mean values and SEMs were calculated 
for the TAG abundances. After a log2 transformation, the Student’s t-test was used to 
compare mean values of the TAG abundances between the PNPLA3 genotype and obese 
subgroups. To calculate q-values, multiple hypothesis testing was used, as described before  
(346). To visualize the comparison between the abundances of TAG molecules with respect 
to their FA chain lengths and the number of double bonds, heatmaps were created. The data 
values on the heatmaps are a log2 of the ratio of the mean values of the case group divided by 
the mean values of the control group. The cells in the heatmap show the significance of the 






8.1  Effect of APOC3 variants on liver fat content (I) 
Characteristics of study groups. APOC3 variant allele (T-455C at rs 2854116, C-482T at 
rs2854117) and wild-type homozygotes (T-455 and C-482) carriers were comparable with 
regard to gender, age, BMI, and body weight. No differences were observed in fP-glucose, 
insulin, HDL, triglyceride, ALT, and AST concentrations. Also, no difference emerged 
regarding the prevalence of the metabolic syndrome (MetS) or DM2 in the two groups.  In 
the clinical and biochemical characteristics, only the total and LDL cholesterol were slightly 
higher (p=0.024, p=0.012) in wild-type than variant allele carriers; other parameters showed 
no difference (Table 3). 
 
Table 3. Characteristics of APOC3 wild-type homozygotes (T-455 and C-482) and variant 













for age and  
gender 
N 53 364   
Age (years) 45±12 44±13 0.58  
Gender (female, % female) 29 (55%) 191 (53%) 0.77  
Metabolic syndrome (%) 68 60 0.30  
Type 2 diabetes (%) 17 27 0.13  
Weight (kg) 91±20 93±23 0.55 0.52 
Waist (cm) 









fP-glucose (mmol/l) 6.1±1.9 6.4±2.0 0.30 0.24 
fS-insulin (mU/l) 11.6±8.3 10.7±7.4 0.46 0.56 
fS-TAG (mmol/l) 1.6±0.8 1.7±1.3 0.77 0.77 
fS-HDL cholesterol (mmol/l) 1.4±0.4 1.4±0.4 0.74 0.79 
fS-LDL cholesterol (mmol/l) 3.2±1,0 2.8±0.9 0.01 0.01 
Total S-cholesterol (mmol/l) 5.3±1.1 4.9±1.0 0.02 0.03 
fS-ALT (U/l) 43.6±36.2 43.7±38.7 0.99 0.94 
fS-AST (U/l) 32.1±13.8 35.2±22.4 0.17 0.15 
Liver fat (%) 4.2 (1.6-12.1) 5.2 (1.4-13.4) 0.53 0.49 
 
Data are shown as mean ± SD, except for liver fat and apoC3, which are shown as median 
and 25th and 75th percentiles. aChi-squared test. *obesity defined as BMI >30 kg/m2. 
Reproduced with permission from the copyright holder (347). 
 
Liver fat content. There was no difference in liver fat content (%) between variant allele 
carriers (5.2% [1.4-13.4]) and wild-type homozygotes (4.2% [1.6-12.1]). The pattern of liver 
fat distribution (Fig. 2) and the prevalence of NAFLD (48% and 43%, respectively) were 
similar in the two groups. When the different genotypes at rs2854117 and rs2854116 were 
analysed separately, the results remained essentially the same. Liver fat content did not differ 
in subjects with NAFLD between wild-type homozygotes and variant allele carriers (14.0% 
[9.4-22.9] and 14.5% [9.2-22.9], respectively), and the same was observed for those wild-
type homozygotes and variant allele carriers without NAFLD (1.7% [1.0-2.7]) and 1.7% [0.7-
3.2]).  When grouped according to haplotypes, both liver fat content and plasma apoC3 
















NAFLD (%) 43 48 0.56a 0.55 






























Figure 2. Upper panel compares the liver fat measured with 1H-MRS and lower panel the 
plasma apolipoprotein C3 concentrations in APOC3 wild-type homozygotes (T-455 and C-
482) and variant allele carriers (T-455C, C-482T, or both). Reproduced with permission from 
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Plasma apoC3 concentrations. Plasma from 132 subjects was available for 
measurement of apoC3 concentrations. There was no difference in the plasma apoC3 
concentrations between wild-type homozygotes and variant allele carriers (Table 3, 
Fig. 3). Also, no difference was seen in apoC3 concentrations between different 
genotypes at rs2854117 and rs2854116.  In variant allele carriers, plasma apoC3 
concentrations were positively associated with liver fat (r=0.33, p<0.0017, Fig. 3), fS-
triglycerides (r=0.39, p<0.0001), total serum cholesterol (r=0.42, p<0.0001) and LDL 
cholesterol (r=0.33, p<0.0001). 
 
 



























Figure 3. Upper upper panel examines the relationship between liver fat content and 
plasma apoC3 concentrations and the lower panel between liver fat content and fS-
triglycerides in APOC3 homozygotes (T-455 and C-482) and variant allele carriers 
(T-455C, C-482T or both). Empty circles represent wild type allele carriers and filled 
black circles variant allele carriers. Scales have been logarithmically transformed. 
Reproduced with permission from the copyright holder (347). 
 
Variance in liver fat. Linear regression analysis was used to compare the genotypic 
effect of APOC3 and PNPLA3 variants on liver fat content. APOC3 alone and 
PNPLA3 alone (n=385) accounted for 0% (p=0.33) and 3.2% (p<0.0001), 
respectively, of the variance of liver fat content. Carriers of the PNPLA3 (rs738409) 
GG-genotype had a 2.7-fold (median 11.3%) higher liver fat than carriers of CC-
genotype (median 4.2%). Gender, age, BMI, and the SNP at rs738409 in PNPLA3 
predicted liver fat independently in multivariate linear regression analysis. 
 
8.2 Prevalence estimate of NASH (II). 
Biopsy studies. In the Finnish biopsy cohort (n=296) 42% had NAFL (n=123), 29% 
had NASH (n=85), and 5.2% had advanced fibrosis (n=15). In the Italian biopsy 
cohort (n= 380) 55% had NAFL (n=211) and 45% had NASH (n=169). The clinical 




‘NASH score’. Variants that were significantly associated with NASH in univariate 
analyses were examined in multivariate logistic regression analysis. In the discovery 
group the AUROC was 0.776 (95% CI 0.701-0.852). Backward multivariate 
regression analyses were used to identify the variables that independently predicted 
NASH.  
Table 5. Clinical characteristics of the patients in the Finnish and Italian biopsy studies. 
 Finnish cohort Italian cohort 
N 296 380 
Age (years) 47±9 48±12 
Gender (% male) 116 (39)  246 (65) 
BMI (kg/m2) 
 (% obese BMI> 30kg/m2) 
43.7±8.6 (91) 31.7±8.4 (40) 
Type 2 diabetes (n, %) 115 (39) 77 (20) 
Metabolic syndrome (n, %) 239 (81) 160 (42) 
fS-ALT (IU/l) 52±39 48±33 
fS-AST (IU/l) 39±25 23±33 
fS-INS (mU/l) 17.0±11.0 20±21 
S-ALB (g/l) 37±4 46±3 
B-Platelets (x109/l) 264±72 222±62 
fS-Triglycerides (mmol/l) 1.6±0.9 1.6±1.4 
fS-HDL cholesterol (mmol/l) 1.2±0.4 1.3±0.4 
fS-LDL cholesterol (mmol/l) 2.5±0.8 3.2±1.0 
PNPLA3 (CC/CG/GG) (n, %) 135 (52) / 100 (38) / 26 
(10) 
152 (40) / 175 (46) / 53 
(14)  
CK18 (U/L) 473±552 298±204 (n=80) 
NAFL (n, %) 123 (42) 211 (55) 
NASH (n, %) 85 (29) 169 (45) 
Data are shown as mean ± SD. ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; ALB, serum albumin; BMI, body mass index; NAFL, non-alcoholic 
fatty liver; NASH, non-alcoholic steatohepatitis.  Reproduced with permission from the 
copyright holder (347) 
 
This model was used to build the NASH score: 
 
-3.05 + 0.562 × PNPLA3 genotype (CC=1, CG=2, GG=3) – 0.0092 × fS-insulin 
(mU/L) + 0.0023 × AST (IU/L) + 0.0019 × (fS-insulin × AST). 
 
The optimal cut-off value to predict NASH was determined using the Youden index. 
In the discovery group, values greater than -1.054 predicted NASH with a sensitivity 
of 75% and a specificity of 74%. 
 
‘NASH liver fat score’. The optimal cut-off to predict NASH for the ‘NASH liver fat 
score’ was 2.122. 
 
Validation of the ‘NASH score’ and the ‘NASH liver fat score’ to predict NASH.  The 
‘NASH score’ was first validated in the remaining Finnish biopsy subjects (n=97) and 
had an AUROC of 0.758 (95% CI 0.626-0.891). NASH was predicted with a 
sensitivity of 65.2% and specificity of 72.9% for the cut-off value of -1.054.  
An external Italian biopsy cohort was used to validate both the ‘NASH score’ and the 
‘NASH liver fat score’. For the ‘NASH score’ the AUROC was 0.759 (95% CI 0.711-
0.807). The cut-off of -1.054 predicted NASH with a sensitivity of 39% and 
specificity of 89%. The AUROC for the ‘NASH liver fat score’ was 0.737 (95% CI 
0.687-0.787) and predicted NASH with a sensitivity of 93% and specificity of 33% 
with the cut-off value of -2.122. 
 
Comparison of the ROC curves. In the Finnish biopsy cohort, the ‘NASH score’ and 
the ‘NASH liver fat score’ had AUROCs of 0.774 (95% CI 0.704-0.839) and 0.734 
(95% CI 0.664-0.805), respectively. The ‘NASH score’ had a PPV and NPV of 53% 
and 86%, and the ‘NASH liver fat score’ 54% and 83%, respectively. In the biopsy 
cohort from Italy the AUROCs for the ‘NASH score’ and the ‘NASH liver fat score’ 
were 0.759 (95% CI 0.711-0.807) and 0.737 (95% CI 0.687-0.787), respectively. For 
the ‘NASH score’ the PPV and the NPV were 65% and 74%, and for the ‘NASH liver 
fat score’ 53% and 85%, respectively. Figure 4 compares the ROC curves in the 
Finnish (left panel) and Italian (right panel) cohorts. The AUROCs of the Finnish and 
Italian biopsy cohorts did not differ significantly from each other. 
 
Figure 4.  
 
Figure 4. ROC-curves. The left panel represents the ROC curves of the two scores to 
predict NASH in the Finnish biopsy cohort, and the right panel in the Italian biopsy 
cohort. The AUROCs were 0.774 (95% CI 0.709-0.839) for the ‘NASH score’ and 
0.734 (95% CI 0.664-0.805) for the ‘NASH liver fat score’ in the Finnish cohort, and 
0.759 (95%CI 0.711-0.807) and 0.737 (95%CI 0.687-0.787), respectively, in the 
Italian cohort. The AUROCs did not differ significantly between the cohorts. 
Reproduced with permission from the copyright holder (348). 
 
FIN-D2D study. Table 6 shows the clinical characteristics of the 2849 subjects, 48% 
of whom were male. Their mean age was 60±8 years, and the mean BMI was 
27.5±4.8kg/m2. 25% were obese, 17% had DM2, and 57% had MetS. 
 
Table 6. Clinical characteristics of the FIN-D2D study subjects. 
N 2849 
Age (years) 60±8 
Gender (% male) 1357 (48%) 
BMI (kg/m2) 27.5± 4.8 
Type 2 Diabetes (n, %) 479 (17%) 
 
 
Prevalence estimate. According to the ‘NASH score’, the population-based 
prevalence estimate of NASH in the D2D cohort was 6.0% (95% CI 5.0-6.9) and 
according to the ‘NASH liver fat score’ 4.2% (95% CI 3.4-5.0) (Table 6). Based on 
the ‘NASH score’, in subjects with DM2 in the D2D cohort the prevalence of NASH 
was 17.6% (95% CI 13.9-21.2), whereas in those without DM2 it was 3.7% (95% CI 
2.9-4.5%) (P<0.0001). In the obese the prevalence estimate of NASH was 14.6% 
(95% CI 11.8-17.4) and in the ‘non-obese’ 3.2% (95% CI 2.4-4.0) (p<0.0001). The 
prevalence of NASH in men and women was 7.8% and 5.0% (p=0.00528). 
Metabolic Syndrome (n, %) 1625 (57%) 
S-ALT (IU/l) 27±17 
S-AST(IU/l) 26±13 
fS-INS 8.8±16.4 
fS-Triglycerides (mmol/l) 1.4±0.8 
fS-HDL cholesterol (mmol/l) 1.4±0.3 
fS-LDL cholesterol (mmol/l) 3.4±0.9 
PNPLA3 (CC/CG/GG) 1666 (61.1%) /936 (34.3%) /125 (4.6%) 
Score NAFLD* (n, %) 
Score NAFL* (score NAFLD– score NASH) 
1010 (39.5 % [95%CI: 37.6 - 41.4]) 
862 (33.8%) 
Score-NASH** (n, %) 
NASH Liver Fat Score (cut-off 2.122) 
NASH Score (cut-off -1.054) 
 
107 (4.2% [95%CI: 3.4 - 5.0) 
149 (6.0 % [95%CI: 5.0 - 6.9) 
 
Data are shown as mean ± SD. ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; ALB, serum albumin; BMI, body mass index; NAFLD, non-alcoholic 
fatty liver disease; NASH, non-alcoholic steatohepatitis. *NAFLD calculated based on the 
NAFLD liver fat score (available for 2554 subjects) (306). **NASH calculated based on 
the two NASH scores (available for 2497 subjects).  Reproduced with permission from the 
copyright holder (348). 
 
Sensitivity analyses. The Bayesian model was used for sensitivity analyses. The 
sensitivity and specificity of the ‘NASH score’ were assumed to range from 0.7 to 1 
based on the results of the Finnish biopsy cohort. Using this method, the population-
based prevalence of NASH was 3.60% (95% stimulation limits: 0.16%, 7.69%), 
Assuming that the sensitivity and specificity of the ‘NASH liver fat score’ ranges 
from 0.55 to 1 and 0.7 to 1, the prevalence of NASH was found to be 3.1% (95% 
stimulation limits: 0.2%, 6.8%). 
 
8.3 Triacylglyceride signature in NAFLD (III). 
 
Study group characteristics.  
PNPLA3 subgroups. The PNPLA3148MM/148MI and the PNPLA3148II groups did not 
differ in age, sex, and BMI (Table 7, Fig. 5). The liver fat content was markedly 
higher in the PNPLA3148MM/148MI group (10.5± 0.7%) than in the PNPLA3148II group 
(8.6 ± 0.6%, p<0.05). HDL and LDL cholesterol as well as serum insulin were similar 
in the groups. The PNPLA3148MM/148MI group had marginally, but not significantly 
(p=0.10) lower serum total TAG concentrations than the PNPLA3148II group (Table 7). 
 
Obese and ‘non-obese’ subgroups. No difference was present between the obese and 
the ‘non-obese’ groups concerning age, sex, and the PNPLA3 genotype (Table 7). In 
the obese group, the mean BMI was 42.1±0.5 kg/m2 and in the ‘non-obese’ group 
28.9±0.3 kg/m2 (Table 7, Fig. 5). The obese group had a markedly higher liver fat 
content (11.65±0.7%) than the ‘non-obese’ group (7.5±0.5%, p<0.0005) group (Table 
7, Fig. 5). Compared with the ‘non-obese group, in the obese group the serum insulin 
concentration (15.6±0.7 mU/l vs. 9.9±0.5mU/l, p<0.0005), as well as the TAG 
concentrations were markedly higher, whereas the HDL and LDL cholesterol 
concentrations were lower (Table 7). 
 
‘PNPLA3 NAFLD’ vs. ‘Obese NAFLD’. Forty-seven subjects were found to have 
‘PNPLA3 NAFLD’ and 51 subjects ‘obese NAFLD’. Liver fat was similar between 
the groups (Table 7). The ‘PNPLA3 NAFLD’ subjects had a mean BMI of 29.6±0.4 
kg/m2 and the ‘obese NAFLD’ 41.0±0.9 kg/m2 (p<0.0001). The mean serum insulin 
concentration was markedly higher in the ‘obese NAFLD’ group (15.7±1.0 mU/l) 
 
than in the ‘PNPLA3 NAFLD’ group 12.3±0.9mU/l, p<0.001). There were no 
differences with regard to serum total TAG or HDL and LDL cholesterol between the 
groups. 
 
Figure 5. Comparison of BMI, liver fat content and fS-insulin between 

































Figure 5. BMI (top panel), liver fat content (middle panel), and fasting serum (fS) 
insulin concentrations (bottom panel) between PNPLA3148II and PNPLA3148MM/148MI 
groups, and between obese and ‘non-obese’ groups. Data are shown as mean ± SEM. 
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 the copyright holder (348). 
 
Cluster analysis. 
Altogether 413 molecular lipids were measured using the UPLC-MS based analytical 
platform, and 161 of these were identified. The lipidome was first assessed by clustering the 
data into a cluster subset of 11 lipid clusters using Bayesian model-based clustering (345). To 
a large extent, the clusters followed different functional or structural groups of lipids. Only 
LC1, which contained only TAGs, differed markedly between the PNPLA3148MM/148MI and 
PNPLA3148II groups (Fig. 6). Therefore, this cluster was the target for further analysis. There 
were also differences in the lipid clusters between the obese and the ‘non-obese’ groups, but 
they were not included in further analysis. 
 
Figure 6.  
 
Figure 6. The upper panel represents the mean lipid concentrations within each cluster 
between PNPLA3148II and PNPLA3148MM/148MI groups and the lower panel between obese and 
‘non-obese’ groups. Statistical comparison performed by two-sided t test. *p<0.05, **p<0.01, 
***p<0.001. Reproduced with permission from the copyright holder (349). 
 
Absolute TAG concentrations. In the PNPLA3148MM/148MI group the absolute concentrations of 
several TAG species were significantly lower than in the PNPLA3148II group. These TAGs 
consisted of both major (most abundant) and minor TAG species, most of them containing an 
oleic acid (18:1) acyl group. 
Compared with the ‘non-obese’ group the absolute concentrations of several TAGs were 
markedly increased in the obese group. The most abundant TAG was (16:0/18:1/18:1), which 
was higher in the obese group (168±7 mmol/l) than in the ‘non-obese’ group (148±5  mmol/l, 
p=0.0042). In contrast, the same TAG (16:0/18:1/18:1) was lower in the PNPLA3148II group 
(148±4 mmol/l) than in the PNPLA3148MM/148MI group (169±6 mmol/l, p=0.026). Also, the 
absolute concentrations of various other, long-chain fatty acyl-containing TAGs (with 51-58 
carbon bonds and 2-9 double bonds) were markedly higher in the obese group. In contrast, 
the obese group had lower absolute concentrations of short-chain TAGs (42-22 carbon 
bonds) than in the ‘non-obese’ group (Fig. 8, left panel). A similar pattern was observed in 
absolute concentrations of TAGs between the ‘obese NAFLD’ vs. the ‘PNPLA3 NAFLD’ 
groups (Fig. 9). The comparison of absolute concentrations of TAGs between the PNPLA3, 







Figure 7. TAG concentrations in the PNPLA3 subgroups. 
 
Figure 7.  The left panel represents the absolute and the right panel the relative 
concentrations of TAGs between PNPLA3148MM/148MI and PNPLA3148II groups. The 
colour code indicates the logarithm of the ratio between means of the groups for an individual 
TAG. Blue indicates a decrease in the variant allele carriers (PNPLA3148MM/148M) relative to 










Figure 8. TAG concentrations in the obese and the ‘non-obese’ subgroups 
 
Figure 8. The left panel represents the absolute and the right panel the relative 
concentrations of TAGs between Obese and ‘Non-obese’ groups. The colour code 
indicates the logarithm of the ratio between means of the groups for an individual TAG. Blue 
denotes a decrease and red an increase in the obese relative to the ‘non-obese’. Reproduced 
with permission from the copyright holder (349). 
 
Relative TAG concentrations. The relative TAG distribution was calculated as concentration 
of individual TAGs divided by all measured TAGs by UPLC-MS. In the PNPLA3148MM/148MI 
group, the relative concentrations of three long-chain TAGs were markedly decreased as 
compared with the PNPLA3148II group: 52:1 (TAG [16:0/18:0/18:1]), 53:2 (TAG 
[17:0/18:1/18:1]), and 54:2 (TAG [18:0/18:1/18:1] or TAG [16:0/18:1/20:1]) (Fig. 7, right 
panel). This pattern of distribution differed markedly from that seen in the obese vs. the ‘non-
obese’ groups (Fig. 8, right panel). In the obese group, long-chain polyunsaturaturated TAGs 
were relatively increased, whereas the relative concentrations of short-chain TAGs with a few 
double bonds were decreased (Fig. 9). The differences observed in the absolute 
 
concentrations of 51-54 carbon chain TAGs between the obese and the ‘non-obese’ groups 
disappeared when analysed using their relative concentrations (Fig. 8). The relative 
distribution pattern of TAGs between the ‘PNPLA3 NAFLD’ and the ‘obese NAFLD’ groups 
showed differences in the most abundant TAGs 52:2 and 52:3, but otherwise approximated 
the pattern seen between the obese and the ‘non-obese’ groups (Fig. 8). 
 
Figure 9. TAG concentrations in the ‘PNPLA3 NAFLD’ and ‘obese NAFLD’ groups 
 
Figure 9. The panel on the left represents the absolute and the panel on the right the 
relative concentrations of TAGs between ‘PNPLA3 NAFLD’ and ‘obese NAFLD’ 
groups. The colour code indicates the logarithm of the ratio between means of the groups for 
an individual TAG. Blue denotes a decrease and red an increase in the ‘PNPLA3 NAFLD’ 
groups compared with the ‘obese NAFLD’ group. Reproduced with permission from the 




The global obesity epidemic parallels the increases in metabolic syndrome and non-alcoholic 
fatty liver disease (NAFLD), but not all obese subjects develop these conditions, and lean 
individuals can be insulin-resistant and/or have NAFLD (350, 351). Family studies suggest 
the heritability of NAFLD to be considerable (141). In the present study, we examined 
heterogeneity of NAFLD by investigating whether genetic variants in APOCIII are associated 
with NAFLD (I) and whether PNPLA3 I148M gene variant influences the circulating 
lipidome in a different way than NAFLD associated with obesity and insulin resistance (III). 
Only a fraction of patients with simple steatosis progresses to develop NASH. No data exist 
on the prevalence of NASH in population-based studies using a biopsy-validated score for 
NASH. Therefore, we developed a clinical score to predict NASH and used it to estimate the 
population-based prevalence of NASH (II).  
 
9.1 Effect of APOC3 variants on liver fat content (I) 
In Study I variants in APOC3 alone explained 0% (p=0.33), PNPLA3 alone 3.2% (p<0.0001), 
and the two combined 2.9% (p=0.18 for APOC3 and p<0.0001 for PNPLA3) of the variance 
in liver fat. The APOC3 wild-type homozygotes (T-455 and C-482) and variant allele carriers 
(T-455C at rs2854116, C-482T at rs2854117, or both) did not significantly differ with respect 
to liver fat content, NAFLD prevalence, plasma TAG or apoC3 concentrations. These data 
suggest that in the present study group APOC3 gene variants do not confer susceptibility to 
increased liver fat content. 
 
A study by Petersen et al. (10) in a cohort of 95 Asian Indian men and a validation cohort of 
164 non-Asian Indian men had opposing results to ours. In their study, the prevalence of 
NAFLD was higher in the variant allele carriers, who also had higher TAG and apoC3 
concentrations than the wild-type carriers (10). As in our study, the liver fat content was 
measured using H-MRS. Our study cohort differed from that of Petersen et al., as our 
subjects were obese and had metabolic abnormalities, whereas those in the study of Petersen 
et al. had a normal BMI and lower prevalence of NAFLD. On the other hand, the advantage 
of our study is a larger sample size (417 vs. 95 and 164 subjects). Our study could not 
replicate the association between APOC3 variants and liver fat observed by Petersen et al. 
(10). Thus, ethnicity may have had an influence on the association between APOC3 genetic 
variation and liver steatosis. Nonetheless, consecutive studies in Hispanic, European 
 
American, African American and European subjects have also failed to confirm the 
association between APOC3 variants and NAFLD (352-356). 
 
The robust association between PNPLA3 and NAFLD has been confirmed in seven of eight 
genome-wide association studies (122). In the study of Petersen et al. (10), APOC3 variants 
alone explained 11.0% and PNPLA3 alone 6.5% of the variance in risk of NAFLD. Our study 
did not find an association between APOC3 and liver fat content, whereas the PNPLA3 
I148M explained 3.2% of the variance in liver fat content. The larger cohort or the wider 
distribution of liver fat in our study could explain the lower percentage.  
 
The differences observed in the variance in liver fat could also be explained by differences in 
prevalence of the GG genotype at rs738409, which was 6.6% in our study cohort, being 
comparable to the reported frequencies in other European cohorts (202, 357). This data was 
not reported by Petersen et al (10). One limitation in our study is that one of the SNPs, the 
rs2854116, deviated from the Hardy-Weinberg equilibrium (p=0.03), whereas the other 
genotype frequencies at rs738409 and rs2854117 were in equilibrium. 
 
Consistent with previous studies, the plasma apoC3 concentrations were positively correlated 
with plasma TAG and LDL concentrations (358-361). In contrast to previous studies (10, 
362) we did not observe hypertriglyceridemia in the APOC3 variant allele carriers in our 
cohort, which could be due to limited availability of apoC3 data (n=132 subjects). ApoC3 is 
known to inhibit LPL (363), and thus, its higher availability could lower the clearance of 
plasma TAGs, reflected as a positive correlation between the two. On the other hand, as most 
of the circulating apoC3 is found to be bound to VLDL, the positive correlation could be 
explained by the increased VLDL-TAG production seen in NALFD (363). As we lack the 
turnover data for apoC3 and VLDL, we cannot differentiate between these two possibilities. 
In conclusion, variants in APOC3 do not appear to explain variance in liver fat content in 
Finns and, unlike in PNPLA3, ethnicity could play a role in the effect of genetic variation in 
APOC3 on NAFLD. 
 
9.2 ‘NASH score’ and population-based prevalence estimate of NASH (II) 
In Study II, to our knowledge we established for the first time, a histologically validated 
score to predict NASH and to estimate the population-based prevalence of NASH. In the 
Finnish cohort of 296 bariatric surgery patients, AST, the PNPLA3 genotype, and fasting 
 
insulin were found to best predict NASH. These were used to create the ‘NASH score’, 
which had an AUROC of 0.774 (95% CI 0.709-0.839) in the entire Finnish cohort. The score 
was validated in an Italian cohort consisting mainly of non-bariatric surgery patients with a 
mean BMI approximating that of the D2D cohort. The AUROC of the ‘NASH score’ in the 
Italian cohort was 0.759 (95% CI 0.711-0.807), being comparable to that in the Finns. We 
also determined new cut-offs for NASH for a previously validated NAFLD liver fat score 
(306). This score, termed the ‘NASH liver fat score’, performed more modestly than the 
‘NASH score’, but the AUROCs were again similar in the Finnish (0.734 [95% CI 0.664-
0.805]) and the Italian cohorts (0.737 [95% CI 0.687-0.787]). The NASH prevalence was 
estimated in the population-based D2D cohort to be 6.0% using the ‘NASH score’ and 4.2% 
using the ‘NASH liver fat score’. The mean prevalence estimates for the scores using the 
Bayesian sensitivity analyses were 3.6% and 3.1%, respectively.  
 
The most important limitation in our study is the modest performance of the ‘NASH score’; 
the AUROC is good at best. The AUROC is similar to that seen in a meta-analysis of 494 
severely obese French subjects (364), but is somewhat worse than the NICE model developed 
in a cohort of 464 morbidly obese patients, which consisted of the parameters ALT, CK18, 
and metabolic syndrome (316). The ‘NASH liver fat score’ had a moderate AUROC of 0.73. 
 
Additional scores have been developed after the Study II, including a clinical model for 
NASH in diabetic NAFLD patients, containing the parameters of white race, BMI, waist, 
ALT, AST, albumin, HbA1c, HOMA-IR, and ferritin (326). This score had a slightly better 
AUROC than that of the ‘NASH score’ but was developed to diagnose NASH only in 
diabetics. The NASH ClinLipMet Score was developed in a Finnish biopsy cohort of 318 
subjects and had a markedly better AUROC (0.87) than the ‘NASH score’ (300). As a 
drawback, in addition to clinical data, the score contains variables of lipids and metabolites, 
which are not yet routinely available in the clinic (300). 
 
The prevalence estimate of NASH based on the ‘NASH score’ and ‘NASH liver fat score’ is 
likely to be a gross overestimation of the true prevalence of NASH. This is supported by the 
lower prevalence estimate for both scores when using the Bayesian model. When applying 
the ‘NASH score’, a sensitivity of 71.6% means that 28.4% of those with NASH will be 
missed, whereas a specificity of 73.5% means 26.5% will be wrongly diagnosed as having 
the disease. The number of patients with a false-positive diagnosis is therefore too high for 
 
the ‘NASH score’ to be useful in the clinics for diagnosis of NASH. The Bayesian estimate 
of the mean prevalence rate and its confidence limits further highlights the limitations of the 
score. Nonetheless, the ‘NASH score’ could be of use in identifying patients needing referral 
to a hepatologist. 
 
The NASH prevalence of 29% in the Finnish biopsy cohort was comparable to previous 
studies, in which the prevalence has ranged between 18-37%  (77-79, 96, 97, 317, 365-368). 
Although the ‘NASH score’ was developed in a morbidly obese cohort and applied to a less 
obese D2D group, we are unaware of data showing that NASH would differ in less obese 
subjects. To overcome this limitation, both the ‘NASH score’ and the ‘NASH liver fat score’ 
were validated in the Italian cohort, which has a BMI was similar to that in the D2D cohort. 
 
Another population-based estimate of NASH was carried out in the NHANES survey by 
Younossi et al. (369). In that study, NASH was assumed in patients who had NAFLD in 
combination with diabetes or HOMA > 3 (369), i.e. a clinical evaluation rather than a 
histologically validated score. Using this definition, the prevalence estimate of NASH in our 
biopsy cohort was markedly higher than the true prevalence of NASH (44% vs. 29%), 
suggesting that the NHANES survey prevalence estimate is an overestimation of the true 
prevalence of NASH (369). The prevalence of 1.1% in the 2005-2008 NHANES survey may 
seem low compared with the prevalence estimate of ~5% in the D2D sample, but the study 
samples differ considerably in their mean age, for example, which was ~45 years in the 
NHANES study (369) and 45-74 years in the D2D cohort. A systematic review from 2011 
estimated the prevalence of NASH to be 3-5% (58). 
 
NASH prevalence is dependent on ethnicity (58). As the NAFLD liver fat score has been 
validated in the diagnosis of NAFLD in other Caucasian subjects, such as Italians (370) and 
the Dutch (371), the present prevalence estimate of NASH could be applicable to Caucasians. 
In conclusion, Study II aimed to create a NASH score after testing for major factors 
previously found to be associated with NASH (50), including fS-insulin, PNPLA3 genotype, 
CK-18 fragments, and such clinical parameters as age, gender, liver enzymes, albumin, 
platelets, glucose, BMI, and waist circumference. A NASH score was developed and 
validated, and subsequently used to estimate the population prevalence of NASH, which was 
found to be ~5%. 
 
 
9.3 Triacylglyceride signature and subtypes in NAFLD (III) 
In Study III, we found the circulating TAG profiles to be markedly different between 
NAFLD associated with the PNPLA3 I148M variant independent of obesity, and NAFLD 
associated with obesity independent of the PNPLA3 genotype. Both the ‘PNPLA3 NAFLD’ 
and the ‘obese NAFLD’ showed specific changes in the absolute and relative distribution of 
circulating TAGs, which can be associated with obesity/insulin resistance rather than with 
liver total TAG concentrations (Fig. 9). The relative TAG distribution was analysed to 
eliminate the effect of differences in total TAG concentrations. 
 
The 372 subjects were divided into two groups on the basis of their PNPLA3 genotype at 
rs739409. One group contained one (GC) or two (GG) of the variant alleles 
(PNPLA3148MM/MI), and the other group was homozygous for the wild-type allele (CC) 
(PNPLA3148II). Unsurprisingly, the group containing the variant allele had markedly higher 
liver fat content than the wild-type homozygotes, and the PNPLA3148MM/MI subjects did not 
exhibit hypertriglyceridemia or low HDL cholesterol concentrations. This is in agreement 
with the majority of previous studies showing that fatty liver due to the I148M mutation in 
PNPLA3 is not accompanied by the metabolic changes usually seen in NAFLD (3, 6). Serum 
total triglycerides were somewhat lower in the PNPLA3148MM/MI group than in the 
PNPLA3148II group, which is also in line with other studies (204, 372, 373).  
 
The increased liver fat in the PNPLA3148MM/MI group was not associated with fasting insulin 
concentrations (Fig. 5). Hepatic insulin sensitivity can be assessed using fasting insulin, 
although the direct method is preferred (329). Normal fasting insulin concentrations in 
subjects with ‘PNPLA3 NAFLD’ are in line with earlier studies reporting fasting insulin 
concentrations (155, 204, 374). Included in these studies is our previous study on insulin 
sensitivity of the liver in 109 subjects measured directly using the euglycemic-
hyperinsulinemic clamp technique (5), as well as another study performing direct 
measurement of insulin sensitivity (8). At least two studies have shown opposing results. 
These include the study on morbidly obese subjects by Palmer et al. (373), as well as a study 
in the Chinese, both reporting an association between the PNPLA3148MM/MI variant and 
hyperinsulinemia (375). In the latter study, however, carriers of the PNPLA3 mutation were 
more obese than the wild-type carriers. To sum up, the majority of studies propose the 
‘PNPLA3 NAFLD’ to not be accompanied by insulin resistance. 
 
 
When comparing the lipid clusters (LCs) between the PNPLA3148MM/MI and PNPLA3148II 
groups, only one LC containing only TAGs (Fig. 6) was found to differ, and thus, was 
included in further analysis. When comparing the PNPLA3 groups, the relative distribution 
pattern of individual circulating TAGs showed that TAG substrates, especially those that 
contained an oleic acid (18:1) moiety preferred by adiponutrin in the liver of mice 
overexpressing PNPLA3148MM/MI (164), were markedly depleted in the variant allele carriers 
(Fig. 7). The differences were apparent in relatively minor TAG species, although a tendency 
for relative depletion in the ‘PNPLA3 NALFD’ group was also seen in the more abundant 
TAG species containing the 18:1 FAs. Therefore, ‘PNPLA3 NAFLD’ might not be 
characterized by an increase in VLDL production, as is the case in ‘obese NAFLD’ (166). It 
has been shown in humans that, irrespective of the extent of steatosis, PNPLA3 variant allele 
carriers have a lower rate of VLDL1 and apoB100 production rather than clearance, which is 
in line with our finding (166). Also, the insulin sensitivity of lipolysis is comparable between 
the variant allele carriers and the non-carriers (174). Therefore, depletion instead of an 
increase of a subset of circulating TAGs seen in our study supports the hypothesis of the 
PNPLA3 I148M variant allele preventing (169) rather than stimulating (168) hepatocellular 
TAG synthesis. 
 
It remains unclear how the I148M variant allele impedes the coupling of stored TAGs and 
VLDL synthesis. As most TAGs which are stored as lipid droplets undergo hydrolysis before 
being reassembled into VLDL-TAG (376), the mutation in PNPLA3 could prevent TAG 
lipolysis at the surface of lipid droplets via manipulation of the adipose triglyceride lipase 
(ATGL) activity (377), which could be reflected as decreased VLDL production. In line with 
this, in vitro data with cells overexpressing the PNPLA3 I148M variant allele show a higher 
neutral lipid content and a decreased secretion of apoB100 relative to the wild-type carriers 
(166). In addition, theoretically, the decreased TAG lipolysis could lead to the accumulation 
of metabolically inert TAGs in lipid droplets, thus reducing the amount of harmful lipid 
intermediates such as diacylglycerides and ceramides  (376). This would explain the lack of 
insulin resistance in the variant allele carriers. Consistent with this hypothesis, cells 
overexpressing the PNPLA3 variant have larger lipid droplets (377), and similar increases in 
liver fat are associated with a ceramide-enriched liver lipidome in 'obese NAFLD' but not in 
'PNPLA3 NAFLD’ (11). 
 
 
Dividing the 372 subjects into obese and ‘non-obese’ groups based on their median BMI, 
showed the liver fat content to be markedly higher in the obese group (Table 7). The obese 
group displayed various alterations in the LCs (Fig. 6) and in the relative TAG distribution 
(Fig. 8) compared with the ‘non-obese’ group. These differences could be due to obesity/ 
insulin resistance or the difference in liver fat content. Comparing the ‘obese NAFLD’ and  
‘PNPLA3 NAFLD’ groups, similar differences in the relative TAG profiles were observed 
(Fig. 9) as in the ‘obese’ and ‘non-obese’ groups. This implies that the differences in the 
TAG profiles were not attributable to higher liver fat content per se. The lack of specific 
TAGs in the PNPLA3148MM/MI group relative to the PNPLA3148II group was not the case when 
comparing the ‘PNPLA3 NAFLD’ and ‘obese NAFLD’ groups. This implies that the 
influence of obesity/insulin resistance on the TAG profile is more important than the 
relatively minor changes seen in the ‘PNPLA3 NAFLD’. The differences observed between 
the obese and the ‘non-obese’ TAG profiles could be explained by either clearance of VLDL 
or its production (378). As the inability of insulin to normally suppress VLDL synthesis 
appears to be the most important mechanism of hypertriglyceridemia in obese NAFLD 
subjects (379), in this case increased VLDL production seems more likely. It has been shown 
that the VLDL composition in NAFLD patients resembles the composition of hepatocellular 
TAGs, implying that ‘obese NAFLD’ subjects’ liver overproduces VLDL-TAGs 
proportionally to increased TAG production (24). 
The lipid and fatty acid compositions of lipoprotein fractions have been previously measured 
in subjects with a wide range of insulin sensitivity (299), as has the rate of production of 
individual TAGs in the splanchnic bed of NAFLD patients (299). Insulin resistance was 
positively correlated with the relative serum concentrations of 16:0, 16:1 and 18:0 esterified 
fatty acids, whereas the concentrations of essential fatty acids were negatively correlated with 
insulin resistance (380). Also, liver biopsy samples from fatty livers are enriched in TAGs 
containing saturated and monounsaturated fatty acids (381). In line with this data, the 
absolute serum concentrations of the abundant, saturated and monounsaturated fatty acid 
containing TAGs were markedly increased in the obese group compared with the ‘non-obese’ 
group. Nonetheless, when examining the relative concentrations of these TAGs they did not 
appear to differ between the obese and the ‘non-obese’ groups. Instead, the minor, 
polyunsaturated TAG species were relatively upregulated, and the short-chain TAG species 
with less double bonds were down-regulated in the obese group (Figs. 8 and 9). The reason 
behind these changes cannot be currently established. 
 
 
In conclusion, our data suggest that NAFLD is heterogeneous, and at least two different 
forms exist. The ‘PNPLA3 NAFLD’ is marked by absolute and relative deficiencies in 
specific circulating TAGs, supporting the hypothesis of the PNPLA3 variant allele being a 
loss-of-function mutation impairing lipolysis, rather than a gain-of-function mutation. When 
comparing ‘obese NAFLD’ and ‘PNPLA3 NAFLD’, various changes in the absolute and 
relative TAG concentrations are seen, which are attributable to obesity/insulin resistance 




10. SUMMARY AND CONCLUSIONS  
 
I) Genetic variants in APOC3 do not appear to contribute to liver fat in Finns. Therefore, 
unlike variants in PNPLA3, ethnicity might influence the effect of APOC3 on NAFLD.  
 
II) We developed and validated a score to predict NASH, which included the parameters 
AST, PNPLA3 genotype, and fS-insulin. This ‘NASH score’ was used to estimate the 
prevalence of NASH in a population-based D2D study. The prevalence of NASH was ~5%. 
 
III) The aetiology of NAFLD influences circulating TAG concentrations. ‘PNPLA3 
NAFLD’ is characterized by absolute deficiency of circulating TAG concentrations, 
supporting the loss-of-function theory in the PNPLA3 I148M variant. ‘Obese NAFLD’ is 
associated with absolute increases in circulating TAGs. These changes can be attributed to 
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